WO2000010563A1 - Novel substituted triazole compounds - Google Patents

Novel substituted triazole compounds Download PDF

Info

Publication number
WO2000010563A1
WO2000010563A1 PCT/US1999/018640 US9918640W WO0010563A1 WO 2000010563 A1 WO2000010563 A1 WO 2000010563A1 US 9918640 W US9918640 W US 9918640W WO 0010563 A1 WO0010563 A1 WO 0010563A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
optionally substituted
aryl
heteroaryl
hydrogen
Prior art date
Application number
PCT/US1999/018640
Other languages
French (fr)
Inventor
Jerry L. Adams
Dennis Lee
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to EP99942232A priority Critical patent/EP1112070B1/en
Priority to DE69917296T priority patent/DE69917296T2/en
Priority to AT99942232T priority patent/ATE266399T1/en
Priority to US09/762,809 priority patent/US6599910B1/en
Priority to CA002341370A priority patent/CA2341370A1/en
Priority to JP2000565884A priority patent/JP2003525201A/en
Publication of WO2000010563A1 publication Critical patent/WO2000010563A1/en
Priority to US10/401,249 priority patent/US7223760B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • This invention relates to a novel group of triazole compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
  • Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell , 80, 179-278 (1995)].
  • protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell , 80, 179-278 (1995)].
  • Protein kinases can be categorized into five classes with the two major classes being, tyrosine kinases and serine / threonine kinases depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine / threonine(s) residues [Hunter, T.. Methods in Enzymology ( " Protein Kinase Classification) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991].
  • kinases For most biological responses, multiple intracellular kinases are involved and an individual kinase can be involved in more than one signaling event. These kinases are often cytosolic and can translocate to the nucleus or the ribosomes where they can affect transcriptional and translational events, respectively. The involvement of kinases in transcriptional control is presently much better understood than their effect on translation as illustrated by the studies on growth factor induced signal transduction involving MAP/ERK kinase [Marshall, C. J. Cell . 80, 179 (1995); Herskowitz, I. Cell . 80, 187 (1995); Hunter, T. Cell . 80, 225 (1995);Seger, R., and Krebs, E. G. FASEB J..
  • cytokines e.g., IL-1 and TNF
  • mediators of inflammation e.g., COX-2, and iNOS
  • LPS bacterial lipopolysaccharide
  • Han (Han, et al, Science 265, 808(1994)] identified murine p38 as a kinase which is tyrosine phosphorylated in response to LPS.
  • Definitive proof of the involvement of the p38 kinase in LPS-stimulated signal transduction pathway leading to the initiation of proinflammatory cytokine biosynthesis was provided by the independent discovery of p38 kinase by Lee [Lee; et al, Nature, 372, 739(1994)] as the molecular target for a novel class of anti-inflammatory agents.
  • CSBP 1 and 2 The discovery of p38 (termed by Lee as CSBP 1 and 2) provided a mechanism of action of a class of anti- inflammatory compounds for which SK&F 86002 was the prototypic example. These compounds inhibited IL- 1 and TNF synthesis in human monocytes at concentrations in the low uM range [Lee, et al., Int. J. Immunopharmac. 10(7), 835(1988)] and exhibited activity in animal models which are refractory to cyclooxygenase inhibitors [Lee; et al, Annals N. Y. Acad. Sci.. 696, 149(1993)].
  • CSBP/p38 is a one of several kinases involved in a stress-response signal transduction pathway which is parallel to and largely independent of the analogous mitogen-activated protein kinase (MAP) kinase cascade ( Figure 1).
  • Stress signals including LPS, pro-inflammatory cytokines, oxidants, UV light and osmotic stress, activate kinases upstream from CSBP/p38 which in turn phosphorylate CSBP/p38 at threonine 180 and tyrosine 182 resulting in CSBP/p38 activation.
  • MAPKAP kinase-2 and MAPKAP kinase-3 have been identified as downstream substrates of CSBP/p38 which in turn phosphorylate heat shock protein Hsp 27 ( Figure 2). It is not yet known whether MAPKAP-2, MAPKAP-3, Mnkl or Mnk2 are involved in cytokine biosynthesis or alternatively that inhibitors of CSBP/p38 kinase might regulate cytokine biosynthesis by blocking a yet unidentified substrate downstream from CSBP/p38 [Cohen, P. Trends Cell Biol.. 353-361(1997)].
  • CSBP/p38 kinase inhibitors (SK&F 86002 and SB 203580) also decrease the synthesis of a wide variety of pro-inflammatory proteins including, EL-6, IL-8, GM-CSF and COX-2.
  • Inhibitors of CSBP/p38 kinase have also been shown to suppress the TNF- induced expression of VCAM-1 on endothelial cells, the TNF-induced phosphorylation and activation of cytosolic PLA2 and the EL- 1 -stimulated synthesis of collagenase and stromelysin.
  • Interleukin-1 IL-1
  • Tumor Necrosis Factor TNF
  • DL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)].
  • the myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.
  • TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, reperfusion injury, graft vs.
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • cachexia secondary to acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis or pyresis.
  • Interleukin-8 is a chemotactic factor produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Its production from endothelial cells is induced by IL-1, TNF, or lipopolysachharide (LPS). IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysozomal enzyme release and respiratory burst from neutrophils.
  • IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis, this may contribute to increased adhesion of the neutrophils to vascular endothelial cells.
  • Many diseases are characterized by massive neutrophil infiltration.
  • Conditions associated with an increased in IL-8 production (which is responsible for chemotaxis of neutrophil into the inflammatory site) would benefit by compounds which are suppressive of IL-8 production.
  • IL-1 and TNF affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
  • CSBP/p38 Inhibition of signal transduction via CSBP/p38, which in addition to IL-1, TNF and IL-8 described above is also required for the synthesis and/or action of several additional pro-inflammatory proteins (i.e., IL-6, GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. This expectation is supported by the potent and diverse anti-inflammatory activities described for CSBP/p38 kinase inhibitors [Badger, et al, J. Pharm. Exp. Thera. 279 (3): 1453- 1461.(1996); Griswold, et al, Pharmacol. Comm. 7, 323-229 (1996)].
  • This invention relates to the novel compounds of Formula (I), (II) and (III) and pharmaceutical compositions comprising a compound of Formula (I), (II) or
  • This invention relates to a method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (III).
  • This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of
  • This invention more specifically relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (HI).
  • This invention more specifically relates to a method of inhibiting the production of IL-6 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (III).
  • This invention more specifically relates to a method of inhibiting the production of EL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (III).
  • This invention more specifically relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II), or (III).
  • Rl is pyrid-4-yl, or pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, Ci-4 alkyl, halogen, hydroxyl, C ⁇ _4 alkoxy, Ci-4 alkylthio, Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, or a N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or
  • Y is X ⁇ -R a ;
  • X1 is sulfur, oxygen, or NH
  • R a is Ci-6alkyl, aryl, arylCi- ⁇ alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylC 1 _6alkyl; and wherein each of these moieties may be optionally substituted;
  • R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri7, C(Z)ORi6,
  • Z is oxygen or sulfur; n is 0, or an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2;
  • R2 is hydrogen, C(H)(A)(R 2 2), (CRl ⁇ R23)n OR9, (CR ⁇ oR23)nOR_ l, Ci-ioalkyl, halo-substituted -io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl,
  • R22 is an optionally substituted C ⁇ _ ⁇ o alkyl
  • Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCj-4 alkyl; and wherein each of these moieties may be optionally substituted;
  • R3 is heterocyclyl, heterocyclylCi-io alkyl or R$;
  • R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
  • R is hydrogen, a pharmaceutically acceptable cation, C -io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl;
  • R7 and R17 is each independently selected from hydrogen or Ci-4 alkyl or R7 and Rl7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15;
  • R8 is Ci-io alkyl, halo-substituted Ci
  • Rl2 is hydrogen or Ri6
  • Rl3 and R14 is each independently selected from hydrogen or optionally substituted Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9;
  • Rl5 is Rio or C(Z)-C ⁇ _4 alkyl
  • Rl6 is Cj-4 alkyl, halo-substituted-C ⁇ .4 alkyl, or C3-7 cycloalkyl
  • Rl8 is Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Cj- ioalkyl, heteroaryl or heteroaryl i-ioalkyl;
  • Rl9 is hydrogen, cyano, C1.4 alkyl, C3-7 cycloalkyl or aryl;
  • R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCj-4 alkyl moiety, all of which may be optionally substituted; or a pharmaceutically acceptable salt thereof.
  • Rl is a pyrid-4-yl, or pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, Ci-4 alkyl, halogen, hydroxyl, Ci-4 alkoxy, Ci-4alkylthio,
  • X is sulfur, oxygen, or NH
  • R a is C ⁇ _6alkyl, aryl, arylCj- ⁇ alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylC ⁇ _6alkyl, wherein each of these moieties may be optionally substituted;
  • R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri7, C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR12, halo-substituted-Ci-4 alkyl, -4 alkyl, ZC(Z)Ri
  • R2 is hydrogen, C(H)(A)(R 22 ), (CRl ⁇ R23)n OR9, (CR ⁇ oR23)nORn, Ci-ioalkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl, C3-7cycloalkylCi-io alkyl, C5.7 cycloalkenyl, C5-7 cycloalkenyl -ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-ioalkyl, heterocyclyl, heterocyclylCi-io alkyl, (CRi 0 R23)nS(O) m Ri8, (CR ⁇ 0 R23)nNHS(O) 2 Rl8, (CRl ⁇ R23)nNRi3Rl4, (CR ⁇ oR23)nNO 2 , (CR ⁇ 0 R23)n
  • A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted Cl-10 alkyl; R22 is an optionally substituted C J. IQ alkyl;
  • Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; and wherein each of these moieties may be optionally substituted;
  • R3 is heterocyclyl, heterocyclylCi-io alkyl or Rs;
  • R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
  • R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3.7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci- o alkanoyl;
  • R7 and R 7 is each
  • Rl7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15;
  • R8 is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CR ⁇ 0 R20)nORi 1, (CR ⁇ oR2 ⁇ )nS(O) m Ri8, (CRioR2 ⁇ )nNHS(O) 2 Rl8, (CRioR20)nNRl3Rl4; and wherein the aryl, arylalkyl, heteroaryl, and heteroarylalkyl moieties may be optionally substituted;
  • R9 is hydrogen, C(Z)R ⁇ 1 or optionally substituted -io alkyl, S(O)2Rl8, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl;
  • RlO and R20 are each independently selected from hydrogen or C _4 alkyl;
  • Rl 1 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl
  • Rl2 is hydrogen or Ri6;
  • R13 and R14 is each independently selected from hydrogen or optionally substituted C -4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9 ;
  • Ri5 is R ⁇ o or C(Z)-Ci-4 alkyl;
  • Rl6 is Ci-4 alkyl, halo-substituted-Ci-4 alkyl, or C3-7 cycloalkyl;
  • Rl8 is Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroaryl i-ioalkyl;
  • R 9 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl or aryl;
  • R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety, all of which may be optionally substituted; or a pharmaceutically acceptable salt thereof.
  • Rl is a pyrid-4-yl, or a pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, C ⁇ _4 alkyl, halogen, hydroxyl, Cj-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, a N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NRi5, or N(R ⁇ o)C(O)R D ;
  • Y is X ⁇ -R a ;
  • X is sulfur, oxygen or NH;
  • R a is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylC _6alkyl, wherein each of these moieties may be optionally substituted;
  • R4 is a phenyl, naphth-1-yl, naphth-2-yl, or a heteroaryl ring, which rings are optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2- yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri7, C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR12,
  • R22 is an optionally substituted C _ ⁇ o alkyl
  • R is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; and wherein each of these moieties may be optionally substituted;
  • R3 is heterocyclyl, heterocyclylC -io alkyl or Rs;
  • R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
  • R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl;
  • R7 and R 7 is each
  • R9 is hydrogen, C(Z)R ⁇ 1 or optionally substituted Ci-io alkyl, S(O)2Rl8. optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl; RlO and R20 are each independently selected from hydrogen or Ci-4 alkyl; Ri is hydrogen, - o alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl
  • Rl2 is hydrogen or R 6;
  • Rl3 and R14 is each independently selected from hydrogen or optionally substituted Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9;
  • Rl5 is Rio or C(Z)-C ⁇ _4 alkyl;
  • R 16 is C 1 -4 alkyl, halo-substituted-C 1.4 alkyl, or C3-7 cycloalkyl;
  • Rl8 is Ci-10 alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci- oalkyl, heteroaryl or heteroaryl i-ioalkyl;
  • Rl9 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl
  • R1 , R2 and R4 moieties are the same.
  • Suitable Rl moieties for use herein include a 4-pyridyl, or 4-pyrimidinyl ring. More preferred is the 4-pyrimdinyl ring.
  • the Ri moiety is optionally substituted one or more times, suitably 1 to 3 times, with Y, optionally substituted C -4 alkyl, halogen, hydroxyl, optionally substituted C _4alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(R ⁇ o)C(O)Rb, N(R ⁇ o)S(O)2Rd» or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NRi5.
  • Y is X ⁇ -R a ; and X is oxygen, sulfur or nitrogen, preferably oxygen.
  • R a is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylC ⁇ _6alkyl, wherein each of these moieties may be optionally substituted as defined herein.
  • R a When R a is aryl, it is preferably phenyl or napthyl. When R a is arylalkyl, it is preferably benzyl or napthylmethyl.
  • R a is a heterocyclic or heterocyclic alkyl moiety, the heterocyclic portion is preferably pyrrolindinyl, piperidinyl, morpholino, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothipyransulfinyl, tetrahydrothio-pyransulfonyl, pyrrolindinyl, indole, or piperonyl ring. It is noted that the heterocyclic rings herein may contain unsaturation, such as in a tryptamine ring.
  • R a is a heteroaryl ring as defined below, it is preferably a pyridine or tetrazole ring.
  • the R a aryl, heterocyclic and heteroaryl rings may be optionally substituted one or more times, preferably one to three times, independently with halogen; Ci-4 alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted alkyl, such as CF3; hydroxy; hydroxy substituted C -4 alkyl; (CR 0R20) _ l-4 alkoxy, such as methoxy or ethoxy; (CR QR20) C 1 S(O) m alkyl and (CR10R20) -S(O) m aryl (wherein m is 0, 1, or 2); (CR ⁇ oR2 ⁇ )q c (O)OR ⁇ 1, such as C(O)Ci-4 alkyl or C(O)OH moieties; (CR ⁇ oR2 ⁇ )q c (°) R l i ; (CR ⁇ oR2 ⁇ )q° (O)R
  • s is an integer having a value of 1, 2, or 3.
  • s is 2 yielding a 1 ,3-dioxyethylene moiety, or ketal functionality.
  • q is 0 or an integer having a value of 1 to 4.
  • Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety; all of which moieties may be optionally substituted as defined below.
  • R c is an -6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety, all of which moieties may be optionally substituted as defined below.
  • R a moiety is an alkyl group it may be optionally substituted as defined herein in the definition section below. Also, the alkyl portion of the R substituents, where applicable, such as the mono- and di-C -6 alkyl amino moieties, may be halo substituted.
  • R a groups include, methyl, ethyl, benzyl, halosubstituted benzyl, napthylmethyl, phenyl, halosubstituted phenyl, aminocarbonylphenyl, alkylphenyl, cyanophenyl, alkylthiophenyl, hydroxyphenyl, alkoxyphenyl, phenoxyphenyl, benzyloxyphenyl, phenylphenyl, methylenedioxyphenyl, trifluoromethylphenyl, methylsulfonylphenyl, tetrazole, methyltetrazolyl, morpholinopropyl, piperonyl, piperidin-4-yl, alkyl substituted piperidine, such as 1 -methyl piperidine, or 2,2,6,6- tetramethylpiperidin-4-yl .
  • Preferred ring substitution on the benzyl or phenyl rings is in the 4-position.
  • Preferred substitution on the phenyl or phenyl alkyl groups is halogen, halosubstituted alkyl or alkyl groups, such as fluoro or chloro, or methyl.
  • Rb is preferably Ci-6 alkyl; preferably Rio is hydrogen. It is also recognized that the Rb moieties, in particular the Ci-6 alkyl group may be optionally substituted, preferably from one to three times, preferably with halogen, such as fluorine, as in trifluoro- methyl or trifluroethyl.
  • the preferred ring placement for the optional substituents on the 4-pyridyl derivative is in the 2-position, and a preferred ring placement on the 4-pyrimidinyl ring is also at the 2-position.
  • a preferred substituent group is methoxy.
  • R4 is a phenyl, naphth-1-yl, naphth-2-yl, or a heteroaryl ring, all of which rings may be optionally substituted, independently, by one or two substituents. More preferably R4 is a phenyl or naphthyl ring. Suitable substitutions for R4 when this is a 4-phenyl, 4-naphth-l-yl,
  • 5-naphth-2-yl or 6-naphth-2-yl moiety are one or two substituents each of which are independently selected from halogen, SR5, SOR5, OR12, CF3, or (CR oR2 ⁇ )vNRl ⁇ R20» and for other positions of substitution on these rings preferred substitution is halogen, S(O) m R3, OR3, CF3, (CRioR20)m"NRi3Ri4, NRioC(Z)R3 and NR ⁇ oS(O) m 'R8.
  • R4 is a heteroaryl ring
  • the ring is substituted in a similar ring substitution pattern as for the phenyl ring as described above,.
  • halogen SR5, SOR5, OR 12, CF3, or (CR ⁇ oR2 ⁇ )vNRl ⁇ R20.
  • Preferred substituents for the 4-position in phenyl and naphth-1-yl and on the 5-position in naphth-2-yl include halogen, especially fluoro and chloro and SR5 and SOR5 wherein R5 is preferably a Ci-2 alkyl, more preferably methyl; of which the fluoro and chloro is more preferred, and most especially preferred is fluoro.
  • Preferred substituents for the 3-position in phenyl and naphth-1-yl rings include: halogen, especially fluoro and chloro; OR3, especially Ci-4 alkoxy; CF3, NR10R2O. such as amino; NRioC(Z)R3, especially NHCO(Ci-io alkyl);
  • NR ⁇ oS(O) m 'R8 especially NHSO2(CMO alkyl), and SR3 and SOR3 wherein R3 is preferably a Ci-2 alkyl, more preferably methyl.
  • R3 is preferably a Ci-2 alkyl, more preferably methyl.
  • R3 may also include hydrogen.
  • the R4 moiety is an unsubstituted or substituted phenyl moiety. More preferably, R4 is phenyl or phenyl substituted at the 4-position with fluoro and/or substituted at the 3-position with fluoro, chloro, Ci-4 alkoxy, methane- sulfonamido or acetamido, or R4 is a phenyl di-substituted at the 3,4-position independently with chloro or fluoro, more preferably chloro. Most preferably, R4 is a 4-fluorophenyl.
  • Z is oxygen or sulfur, preferably oxygen.
  • R3 is heterocyclyl, heterocyclylCi-io alkyl or Rg.
  • R5 is hydrogen, C ⁇ 4 alkyl, C2-4 alkenyl, C2-4 alkynyl or
  • NR7R17 excluding the moieties SR5 being SNR7R17 and SOR5 being SOH.
  • R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, aroyl, or Ci-io alkanoyl.
  • R7 and R17 is each independently selected from hydrogen or Cl-4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15.
  • Rs is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-IO alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CR ⁇ oR20)nORl l, (CR ⁇ oR2 ⁇ )nS(O) m Ri8, (CRioR20)nNHS(O)2Rl8, or CRioR20)nNRl3Rl4; wherein the aryl, arylalkyl, heteroaryl, and heteroarylalkyl containing moieties may be optionally substituted.
  • R9 is hydrogen, C(Z)R ⁇ 1, optionally substituted Ci-io alkyl, S(O)2Rl8» optionally substituted aryl or an optionally substituted aryl-Ci-4 alkyl.
  • Rio and R20 are each independently selected from hydrogen or C 1-4 alkyl.
  • Rl 1 is hydrogen, -io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylCi-io alkyl; and wherein all of these moieties may be optionally substituted.
  • R12 is hydrogen or Ri6; and Rl6 i suitably, C1.4 alkyl, halo- substituted-Ci-4 alkyl, or C3-7 cycloalkyl.
  • R13 and R14 is each independently selected from hydrogen or optionally substituted Cj-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9.
  • R15 is Rio or C(Z)-Ci-4 alkyl.
  • Ri8 is Ci-io alkyl, C3.7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroaryl -ioalkyl.
  • v is 0, or an integer having a value of 1 or 2.
  • n is 0, or the integer 1 or 2.
  • m' is an integer having a value of 1 or 2.
  • n is 0, or an integer having a value of 1 to 10.
  • R2 is hydrogen, C(H)(A)(R 2 2), (CRl ⁇ R23)n OR9, (CR ⁇ oR23)nORl l, Ci-ioalkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl, C3.7cycloalkylC1.io alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-ioalkyl, heterocyclyl, heterocyclylCi-io alkyl, (CR ⁇ oR23)nS(O) m Rl8,
  • R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or a heterocyclylCi-4 alkyl moiety, all of which moieties may be optionally substituted as defined below.
  • R2 is hydrogen, C(H)(A)(R22)> an optionally substituted heterocyclyl ring, and optionally substituted heterocyclylCi-io alkyl, an optionally substituted Ci-io alkyl, an optionally substituted C3_7cycloalkyl, an optionally substituted C3-7cycloalkyl -io alkyl, (CR ⁇ oR23)nC(Z)ORn group,
  • R2 is C(H)(A)(R22) it is recognized that the first methylene carbon in this chain is a tertiary carbon, and it will contain one hydrogen moiety.
  • R2 is a C(AA )(A) moiety, wherein AA is the R22 moiety, but is specifically the side chain residue (R) of an amino acid, as is further described herein.
  • A is an optionally substituted C3-7cycloalkyl, aryl, heteroaryl, or heterocyclic ring, or A is a substituted CJ.JO alkyl moiety.
  • the ring may be substituted independently one or more times, preferably, 1 to 3 times by Ci-io alkyl; halogen; halo substituted -io alkyl, such as CF3; (CR ⁇ oR2 ⁇ )tORl l; (CR ⁇ oR2 ⁇ )tNRl3Rl4, especially amino or mono- or i-C .4 alkylamino; (CRioR2 ⁇ )tS(O) m Rl8 > wherein m is 0, 1 or 2; SH; NR ⁇ o Z)R3 (such NHCO(CMO alkyl)); or NR ⁇ oS(O) m R8 (such as NHSO2(Ci-io alkyl)).
  • t is 0, or an integer of 1 to 4.
  • A is an optionally substituted cycloalkyl it is as defined below in the R22 substitution.
  • the ring is preferably a morpholino, pyrrolidinyl, piperazinyl or a piperidinyl ring.
  • A is an optionally substituted aryl moiety, it is preferably a phenyl ring.
  • the heteroaryl term is as defined below in the definition section.
  • the alkyl chain may be straight or branched. The chain is substituted independently 1 or more times, preferably 1 to 3 times by halogen, such as fluorine, chlorine, bromine or iodine; halosubstituted Ci-io alkyl, such as CF3; C3-7cycloalkyl, Ci-io alkoxy, such as methoxy or ethoxy; hydroxy substituted C -io alkoxy; halosubstituted Cj-io alkoxy, such as OCF2CF2H; OR ⁇ ; S(O)mRi8 (wherein m is 0, 1 or 2); NR13R14; C(Z)NRi3Ri4;
  • A is a C3.7 cycloalkyl, or a C j.g alkyl, more preferably a C j _2 alkyl, i.e. a methylene or ethylene moiety, more preferably a methylene moiety which is substituted by one of the above noted groups.
  • A when A is an alkyl derivative, it is substituted by OR j ⁇ where R 1 is preferably hydrogen, aryl or arylalkyl; NR13R14; OC(Z)R ⁇ 1; or C(Z)OR ⁇ 1- More preferably, A is substituted by R ⁇ ⁇ where Rj j is hydrogen.
  • R22 i a CJ.IQ alkyl chain, which chain may be straight or branched and which may be optionally substituted independently, one or more times, preferably 1 to 3 times, by halogen, such as fluorine, chlorine, bromine or iodine; halo substituted Ci-io alkyl; Ci-io alkoxy, such as methoxy or ethoxy; hydroxy substituted Ci-io alkoxy; halosubstituted -io alkoxy, such as OCF2CF2H; ORi 1 ; S(O) m Ri8;
  • the optional substituents on these cycloalkyl, aryl, heteroaryl, and heterocyclic moieties are as defined herein below. It is noted that those R22 substituent groups which contain carbon as the first connecting group, i.e.
  • R22 is a C g unsubstituted or substituted alkyl group, such as a C 1.3 alkylene, such as methyl, ethyl or isopropyl, or a methylene or ethylene moiety substituted by one of the above noted moieties, or as noted above those substituent groups which contain a carbon may substituent for the first methylene unit of the alkyl chain, such as carboxy, C(O)OR j, C(O)NRi3Ri4, or R22 i an optionally substituted aryl group, such as a benzyl or phenethyl.
  • a C g unsubstituted or substituted alkyl group such as a C 1.3 alkylene, such as methyl, ethyl or isopropyl, or a methylene or ethylene moiety substituted by one of the above noted moieties, or as noted above those substituent groups which contain a carbon may substituent for the first methylene unit of the al
  • R22 is a C
  • R22 alkyl chain is substituted by ORj ⁇ , where Rl 1 is preferably hydrogen, aryl or arylalkyl; S(O)mRi8, where m is 0 and R ⁇ % is a Cj.g alkyl; or an optionally substituted aryl, i.e. a benzyl or phenethyl moiety.
  • R22 i methyl, phenyl, benzyl, CH2OH, or CH2-O-aryl.
  • one or both of A and R22 contain hydroxy moieties, such as in C ⁇ . ⁇ alkyl ORj j, wherein Ri 1 is hydrogen, i.e.CH2CH2OH.
  • Ri 1 is hydrogen, i.e.CH2CH2OH.
  • AAj is the (R) side chain residue of an amino acid, it is a C j_ 5 alkyl group, which may be straight or branched. This means the R group off the core amino acid of the structure R-C(H)(COOH)(NH2).
  • the R residue term is for example, CH3 for alanine, (CI ⁇ CH- for valine, (CH3)2CH-CH2-for leucine, phenyl-CH2- for phenylalanine, CH3-S-CH2-CH2- for methionine, etc.
  • All generally recognized primary amino acids are included in this groups, such as but not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, hydroxylysine, methylhistidine, and other naturally occurring amino acids not found in proteins, such as b-alanine, g-aminobutyric acid, homocysteine, homoserine, citrulline, ornithine, canavanine, djenkolic acid, and b-cyanoalanine, or other naturally occurring non-mammalian amino acids.
  • AAj is the residue of phenylalanine, or alanine.
  • the ring is preferably a morpholino, pyrrolidinyl, piperazinyl, or a piperidinyl group.
  • the substituents may be directly attached to the free nitrogen, such as in the piperidinyl group or pyrrole ring, or on the ring itself.
  • the ring is a piperidine or pyrrole, more preferably piperidine.
  • the R22 heterocyclyl ring may be optionally substituted one to four times independently by halogen; Ci-4 alkyl; aryl, such as phenyl; arylalkyl, such as benzyl,
  • C(O)OR ⁇ 1, such as the C(O)C ⁇ _4 alkyl or C(O)OH moieties; C(O)H; C(O)Ci-4 alkyl; hydroxy substituted Ci-4 alkyl; C1.4 alkoxy; S(O) m Ci-4 alkyl (wherein m is 0, 1, or 2); or NR10R2O (wherein Rio and R20 are independently hydrogen or Ci-4alkyl).
  • the substituents are attached directly on the available nitrogen, i.e. a l-Formyl-4-piperidine, l-benzyl-4-piperidine, l-methyl-4- piperidine, l-ethoxycarbonyl-4-piperidine.
  • the ring is substituted by an alkyl group and the ring is attached in the 4-position, it is preferably substituted in the 2- or 6- position or both, such as 2,2,6,6-tetramethyl-4-piperidine.
  • the substituents are all directly on the available nitrogen.
  • R22 optional substituent is an optionally substituted aryl, it is preferably a phenyl; or when R22 i an optionally substituted heteroaryl ring (as defined in the definition section below), the rings may be optionally substituted independently one or more times, preferably by one to three times by Ci- o alkyl; halogen, especially fluoro or chloro; (CRioR20)tORl 1; (CR oR2 ⁇ )t Ri3Ri4; especially amino or mono- or di-C ⁇ .4 alkylamino; (CRioR2 ⁇ )tS(O) m Rl8.
  • m is 0, 1 or 2; SH; ORi 1 ; NRioC(Z)R3 (such NHCO(Ci-io alkyl)); or NRioS(O) m R8 (such as NHSO2(Ci-io alkyl)).
  • a or R22 is an (optionally) substituted C3-7cycloalkyl group, it is preferably a C3 or C6 ring, most preferably a C3 ring, which ring may be optionally substituted one or more time, preferably 1 to 3 times, independently by halogen, such as fluorine, or chlorine; (CRioR20)tORn; S(O) m Ri8; cyano; (CR ⁇ oR2 ⁇ )t Rl3Rl4; especially amino or mono- or di-C ⁇ .4 alkylamino; N(R ⁇ o)C(O)X ⁇ and Xi is Ci-4 alkyl, aryl or arylCi-4alkyl; Ci-io alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; an optionally substituted alkyl wherein the substituents are halogen, (such as CF3), hydroxy, nitro, cyano, amino, NR
  • R e is a 1,3-dioxyalkylene group of the formula -O-(CH2)s-O-, wherein s is 1 to 3, preferably s is 2 yielding a 1,3-dioxyethylene moiety, or ketal functionality.
  • Rf is NR21R24; alkyl j.g; halosubstituted alkyl ⁇ _6; hydroxy substituted alkyl 1-6; alkenyl 2-6 ; aryl or heteroaryl optionally substituted by halogen, alkyl 1-6, halosubstituted alkyl 1 -6, hydroxyl, or alkoxy ⁇ _6.
  • R21 is hydrogen, or alkyl 1 -6.
  • R24 is hydrogen, alkyl j.g, aryl, benzyl, heteroaryl, alkyl substituted by halogen or hydroxyl, or phenyl substituted by a member selected from the group consisting of halo, cyano, alkyl .5, alkoxy j.g, halosubstituted alkyl ⁇ _6,
  • S(O) m alkyli-6; or R2 and R24 may together with the nitrogen to which they are attached form a ring having 5 to 7 members, which members may be optionally replaced by a heteroatom selected from oxygen, sulfur or nitrogen.
  • the ring may be saturated or contain more than one unsaturated bond.
  • Rf is NR21R24, and more preferably R21 and R24 are both hydrogen.
  • R13 and R 14 are independently hydrogen, C ⁇ _4 alkyl, preferably methyl, or benzyl.
  • Rl 1 is suitably hydrogen, Ci-4 alkyl, especially methyl.
  • Ri8 is preferably aryl, especially phenyl, or a Ci-io alkyl, especially methyl, or ethyl.
  • Rl l is preferably hydrogen, aryl, especially phenyl, or Ci-io alkyl, especially methyl or ethyl.
  • Rl8 is suitably alkyl, especially methyl.
  • R2 is selected from hydrogen, C(H)(A)(R22)» Ci-io alkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylCi-io alkyl, (CR ⁇ oR23)nNS(O) 2 Rl8, (CRl ⁇ R23)nS(O) m Rl8, arylCi-io alkyl, (CRioR23)n Rl3Rl4, optionally substituted C3-7cycloalkyl, or optionally substituted C3-7cycloalkyl -io alkyl.
  • the ring is preferably a morpholino, pyrrolidinyl, piperazinyl, or a piperidinyl group.
  • the substituents may be directly attached to the free nitrogen, such as in the piperidinyl group or pyrrole ring, or on the ring itself.
  • the ring is a piperidine or pyrrole, more preferably piperidine.
  • the heterocyclyl ring may be optionally substituted one to four times independently by halogen; C .4 alkyl; aryl, such as phenyl; aryl alkyl, such as benzyl - wherein the aryl or aryl alkyl moieties themselves may be optionally substituted (as in the definition section below); C(O)OR ⁇ 1, such as the C(O)C ⁇ _4 alkyl or C(O)OH moieties; C(O)H; C(O)C ⁇ _4 alkyl; hydroxy substituted C1.4 alkyl; Ci-4 alkoxy; S(O) m Ci-4 alkyl; or NR ⁇ oR20-
  • the substituents are directly attached on the available nitrogen, i.e. a l-Formyl-4-piperidine, l-benzyl-4-piperidine, l-methyl-4- piperidine, l-ethoxycarbonyl-4-piperidine.
  • the ring is substituted by an alkyl group and the ring is attached in the 4-position, it is preferably substituted in the 2- or 6- position or both, such as 2,2,6,6-tetramethyl-4-piperidine.
  • R2 is an optionally substituted heterocyclyl Ci-io alkyl group
  • the ring is preferably a morpholino, pyrrolidinyl, piperazinyl or a piperidinyl group.
  • the alkyl chain is 1 to 4 carbons, more preferably 3 or 4, and most preferably 3, such as in a propyl group.
  • Preferred heterocyclic alkyl groups include but are not limited to, morpholino ethyl, morpholino propyl, pyrrolidinyl propyl, and piperidinyl propyl moieties.
  • R2 is an optionally substituted C3-7cycloalkyl, or an optionally substituted C3-7cycloalkyl Ci- o alkyl
  • the cycloalkyl group is preferably a C3 or C(, ring, most preferably a C ⁇ ring, which rings may be optionally substituted.
  • the cycloalkyl rings may be optionally substituted one to three times independently by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; OC(O)Rb, Ci-io alkoxy, such as methoxy or ethoxy; S(O) m alkyl, such as methylthio, methylsulfinyl or methylsulfonyl; S(O) m aryl; cyano, nitro; NR7R17; N(R ⁇ o)C(O)X and Xi is Ci-4 alkyl, aryl or arylCi-4alkyl; -io alkyl, such as methyl, ethyl, propyl, isopropyl, or t- butyl; optionally substituted alkyl wherein the substituents are halogen, (such as CF3), hydroxy, nitro, cyano, amino, NR7R17, S(O)m alkyl and
  • Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylC -4alkyl, heterocyclyl, or heterocyclylC ⁇ .4 alkyl; and wherein each of these moieties may be optionally substituted.
  • Rd, Re and Rf are as defined above.
  • R2 cycloalkyl moiety is substituted by NR7R17 group, or NR7R17
  • the substituent is preferably an amino, amino alkyl, or an optionally substituted pyrrolidinyl moiety.
  • those rings may be optionally substituted 1 to 3 times as defined in the definition section.
  • a preferred subgenus of Formula (I) are the compounds of Formula (la) as represented by the general structure:
  • a preferred subgenus of Formula (II) are the compounds of Formula (Ila) represented by the general structure :
  • a preferred subgenus of Formula (III) are compounds of Formula (Ilia) having the general structure :
  • halogen such as fluorine, chlorine, bromine or iodine
  • hydroxy hydroxy substituted Cj-ioalkyl
  • Cj- o alkoxy such as methoxy or ethoxy
  • halosubstituted Ci-io alkoxy S(O)m alkyl, such as methyl thio, methylsulfinyl or methyl sulfonyl
  • NR7R17 such as amino or mono or -disubstituted Cj_4 alkyl or wherein the R7R17 can cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally contains an additional heteroatom selected from O/N/S
  • Ci- o alkyl, C3_7-ycloalkyl, or C3_7cycloalkyl Ci- o alkyl group such as methyl, ethyl
  • Ci-io alkyl such CF2CF2H, or CF3
  • an optionally substituted aryl such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, wherein these aryl containing moieties may also be substituted one to two times by halogen; hydroxy; hydroxy substituted alkyl; C ⁇ _ ⁇ o alkoxy; S(O) alkyl; amino, mono & di-substituted C1.4 alkyl amino, such as in the NR7R 7 group; Cj_4 alkyl, or CF3.
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
  • basic salts of inorganic and organic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and
  • pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety.
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.
  • C ⁇ _ ⁇ o a lkyl or “alkyl” or “alkyl _ ⁇ o” is used herein to mean both straight and branched chain radicals of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, n-propyl, iso- propyl, n-butyl, _ec-butyl, w ⁇ -butyl, tert-butyl, n-pentyl and the like.
  • cycloalkyl is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
  • cycloalkenyl is used herein to mean cyclic radicals, preferably of 5 to 8 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like.
  • alkenyl is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl and the like.
  • aryl is used herein to mean phenyl and naphthyl.
  • heteroaryl (on its own or in any combination, such as “heteroaryloxy”, or “heteroaryl alkyl”) is used herein to mean a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, tetrazole, triazole, imidazole, or benzimidazole.
  • heterocyclic (on its own or in any combination, such as “heterocyclylalkyl”) is used herein to mean a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, or imidazolidine.
  • aralkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean Ci-4 alkyl as defined above attached to an aryl, heteroaryl or heterocyclic moiety as also defined herein unless otherwise indicate.
  • sulfinyl is used herein to mean the oxide S (O) of the corresponding sulfide, the term “thio” refers to the sulfide, and the term “sulfonyl” refers to the fully oxidized S (O)2 moiety.
  • aroyl is used herein to mean C(O)Ar, wherein Ar is as phenyl, naphthyl, or aryl alkyl derivative such as defined above, such group include but are not limited to benzyl and phenethyl.
  • alkanoyl is used herein to mean C(O)Ci-io alkyl wherein the alkyl is as defined above.
  • the compounds of the present invention may exist as stereoisomers, regioisomers, or diastereiomers. These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are included within the scope of the present invention.
  • Exemplified compounds of Formula (I), or pharmaceutically acceptable salts thereof include: l-(Pyrid-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole; 1 -(6-Aminopyrimidin-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole; l-[4-(6,7-Dimethoxyquinazoline)]-3-phenyl-5-(4-fluorophenyl)-l,2,4-triazole;
  • An exemplified compound of Formula (II), or a pharmaceutically acceptable salt thereof is 1 -(4-Fluorophenyl)-3-phenyl-5-(2-aminopyrimidin-4-yl)- 1 ,2,4-triazole.
  • the compounds of Formula (I), (II) and (III) may be obtained by applying synthetic procedures, described herein.
  • the synthesis provided for is applicable to producing compounds of Formula (I), (II) or (III) having a variety of different R ⁇ , R2, and R4 groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed.
  • C(O)NRi3Ri4 from CO2CH3 by heating with or without catalytic metal cyanide, e.g. NaCN, and HNR13R14 in CH3OH; OC(O)R3 from OH with e.g., ClC(O)R3 in pyridine; NR ⁇ o-C(S)NRi3Ri4 from NHR10 with an alkylisothiocyante or thiocyanic acid; NR6C(O)OR6 from NHR6 with the alkyl chloroformate; NR ⁇ oC(O)NRi3Ri4 from NHR10 by treatment with an isocyanate, e.g.
  • Precursors of the groups Rj, R2 and R4 can be other R , R2 and R4 groups which can be interconverted by applying standard techniques for functional group interconversion.
  • I_IQ alkylN3 derivative can be converted to the corresponding C I_IQ alkylN3 derivative by reacting with a suitable azide salt, and thereafter if desired can be reduced to the corresponding C _ o lkylNH2 compound, which in turn can be reacted with Rj S(0)2X wherein X is halo (e.g., chloro) to yield the corresponding C .1 QalkylNHS (0)2R 18 compound.
  • a compound of the formula (I), (II) or (III) where R2 is halosubstituted C ⁇ _iQ- lkyl can be reacted with an amine R13R14NH to yield the corresponding C ⁇ _ ⁇ o-alkylNR 3R 4 compound, or can be reacted with an alkali metal salt of compound.
  • alpha leaving groups for the displacement are halides and sulfonate esters, such as trifates or mesylates and appropriate nucleophiles are may be either organic or inorganic oxygen, nitrogen or sulfur compounds.
  • halides and sulfonate esters such as trifates or mesylates
  • appropriate nucleophiles are may be either organic or inorganic oxygen, nitrogen or sulfur compounds.
  • phenols, alcohols, primary or secondary amines, anilines and either alkyl or aryl sulfides which may be reacted as their metal salts or in the presence of an amine (such as triethylamine or DBU) or inorganic base (such as potassium carbonate) either with or without solvent and heated as required to effect the displacement.
  • an amine such as triethylamine or DBU
  • inorganic base such as potassium carbonate
  • triazoles can be prepared by condensing the acyl chloride with thioamides to form the corresponding monothioimides. The monothioimides are then condensed with arylhydrazines to afford the 1,2,4-triazole nuclei.
  • bases such as sodium hydride, organolithiums or trialkylamines.
  • Suitable protecting groups for use with hydroxyl groups and nitrogen groups are well known in the art and described in many references, for instance, Protecting Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New York, 1981.
  • Suitable examples of hydroxyl protecting groups include silyl ethers, such as t- butyldimethyl or t-butyldiphenyl, and alkyl ethers, such as methyl connected by an alkyl chain of variable link, (CRl ⁇ R2 ⁇ )n-
  • compositions of Formula (I) may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid in the presence of a suitable solvent.
  • the compounds of Formula (I) or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages.
  • Compounds of Formula (I) are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF and are therefore of use in therapy.
  • IL- 1, EL-6, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions.
  • the inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
  • the present invention provides a method of treating a cytokine- mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • Compounds of Formula (I) are capable of inhibiting inducible proinflammatory proteins, such as COX-2, also referred to by many other names such as prostaglandin endoperoxide synthase-2 (PGHS-2) and are therefore of use in therapy.
  • COX-2 also referred to by many other names
  • PGHS-2 prostaglandin endoperoxide synthase-2
  • These proinflammatory lipid mediators of the cyclooxygenase (CO) pathway are produced by the inducible COX-2 enzyme.
  • Regulation, therefore of COX-2 which is responsible for the these products derived from arachidonic acid, such as prostaglandins affect a wide variety of cells and tissues are important and critical inflammatory mediators of a wide variety of disease states and conditions. Expression of COX-1 is not effected by compounds of Formula (I).
  • This selective inhibition of COX-2 may alleviate or spare ulcerogenic liability associated with inhibition of COX-1 thereby inhibiting prostoglandins essential for cytoprotective effects.
  • inhibition of these pro-inflammatory mediators is of benefit in controlling, reducing and alleviating many of these disease states.
  • these inflammatory mediators in particular prostaglandins, have been implicated in pain, such as in the sensitization of pain receptors, or edema.
  • This aspect of pain management therefore includes treatment of neuromuscular pain, headache, cancer pain, and arthritis pain.
  • Compounds of Formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme.
  • the present invention provides a method of inhibiting the synthesis of COX-2 which comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the present invention also provides for a method of prophylaxis treatment in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme.
  • compounds of Formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy of any disease state in a human, or other mammal, which is exacerbated by or caused by excessive or unregulated IL-1, IL-6, IL-8 or TNF production by such mammal's cell, such as, but not limited to, monocytes and/or macrophages.
  • this invention relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • this invention relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, such as osteoporosis, reperfusion injury, graft vs.
  • diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcois
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • AIDS cachexia secondary to acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis ulcerative colitis
  • viruses of Formula (I) are also useful in the treatment of viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo.
  • the viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibiting-compounds of Formula (1).
  • viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses, such as but not limited to, He ⁇ es Zoster and He ⁇ es Simplex.
  • this invention relates to a method of treating a mammal afflicted with a human immunodeficiency virus (HIV) which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. It is also recognized that both IL-6 and IL-8 are produced during rhinovirus
  • HRV HRV infections and contribute to the pathogenesis of common cold and exacerbation of asthma associated with HRV infection
  • HRV infection Turner et al. (1998), Clin. Infec. Dis., Vol 26, p 840; Teren et al. (1997), Am J Respir Crit Care Med vol 155, pl362; Grunberg et al. (1997), Am J Respir Crit Care Med 156:609 and Zhu et al, J Clin Invest (1996), 97:421).
  • Epithelial cells represent the primary site of infection of HRV. Therefore another aspect of the present invention is a method of treatment to reduce inflammation associated with a rhinovirus infection, not necessarily a direct effect on virus itself.
  • Compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than in humans, in need of inhibition of TNF production.
  • TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections.
  • viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.
  • lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.
  • the compounds of Formula (I) may also be used topically in the treatment or prophylaxis of topical disease states mediated by or exacerbated by excessive cytokine production, such as by IL-1 or TNF respectively, such as inflamed joints, eczema, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
  • cytokine production such as by IL-1 or TNF respectively, such as inflamed joints, eczema, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
  • Compounds of Formula (I) have also been shown to inhibit the production of
  • IL-8 Interleukin-8, NAP. Accordingly, in a further aspect, this invention relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • IL-8 has the unique property of promoting neutrophil chemotaxis and activation. Therefore, the inhibition of IL-8 production would lead to a direct reduction in the neutrophil infiltration.
  • the compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine, in particular IL-1, IL-6, IL-8 or TNF, production such that it is regulated down to normal levels, or in some case to subnormal levels, so as to ameliorate or prevent the disease state.
  • Abnormal levels of IL-1, IL-6, IL-8 or TNF constitute: (i) levels of free (not cell bound) IL-1, IL-6, IL-8 or TNF greater than or equal to 1 picogram per ml; (ii) any cell associated IL-1, IL-6, IL-8 or TNF; or (iii) the presence of IL-1, IL-6, IL-8 or TNF mRNA above basal levels in cells or tissues in which IL-1, IL-6, IL-8 or TNF, respectively, is produced.
  • the compounds of Formula (I) are inhibitors of cytokines, specifically IL-1, IL-6, IL-8 and TNF is based upon the effects of the compounds of Formulas (I) on the production of the E -l, IL-8 and TNF in in vitro assays which are described herein.
  • the term "inhibiting the production of IL-1 (IL-6, IL-8 or TNF)” refers to: a) a decrease of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels by inhibition of the in vivo release of the cytokine by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the genomic level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels; c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL- 1 , IL-6, IL-8 or TNF) as a postranslational event; or d) a down regulation, at the translational level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF)
  • TNF mediated disease or disease state refers to any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8.
  • cytokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response.
  • a cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them.
  • a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte.
  • Lymphokines are generally referred to as being produced by lymphocyte cells.
  • cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-a) and Tumor Necrosis Factor beta (TNF- ⁇ ).
  • cytokine interfering or "cytokine suppressive amount” refers to an effective amount of a compound of Formula (I) which will cause a decrease in the in vivo levels of the cytokine to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production.
  • the cytokine referred to in the phrase "inhibition of a cytokine, for use in the treatment of a HIV-infected human” is a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell- mediated HIV gene expression and/or replication and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration.
  • TNF- ⁇ also known as lymphotoxin
  • TNF-a also known as cachectin
  • CSBP MAP kinase
  • RK proinflammatory cytokines
  • cytokine biosynthesis inhibitors of the present invention, compounds of Formula (I) have been determined to be potent and selective inhibitors of CSBP/p38/RK kinase activity. These inhibitors are of aid in determining the signaling pathways involvement in inflammatory responses. In particular, for the first time a definitive signal transduction pathway can be prescribed to the action of lipopolysaccharide in cytokine production in macrophages.
  • CSBP inhibitors were subsequently tested in a number of animal models for anti-inflammatory activity. Model systems were chosen that were relatively insensitive to cyclooxygenase inhibitors in order to reveal the unique activities of cytokine suppressive agents. The inhibitors exhibited significant activity in many such in vivo studies.
  • Chronic diseases which have an inappropriate angiogenic component are various ocular neovasularizations, such as diabetic retinopathy and macular degeneration.
  • Other chronic diseases which have an excessive or increased proliferation of vasculature are tumor growth and metastasis, atherosclerosis, and certain arthritic conditions. Therefore CSBP kinase inhibitors will be of utility in the blocking of the angiogenic component of these disease states.
  • vasculature inappropriate angiogenesis includes, but is not limited to, diseases which are characterized by hemangiomas and ocular diseases.
  • inappropriate angiogenesis includes, but is not limited to, diseases which are characterized by vesicle proliferation with accompanying tissue proliferation, such as occurs in cancer, metastasis, arthritis and atherosclerosis.
  • the present invention provides a method of treating a CSBP kinase mediated disease in a mammal in need thereof, preferably a human, which comprises administering to said mammal, an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
  • This invention therefore, also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.
  • Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions inco ⁇ orating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation.
  • the compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures.
  • the compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg.
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • Compounds of Formula (I) may be administered topically, that is by non- systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base.
  • the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glyeol or a macrogel.
  • the formulation may inco ⁇ orate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C. for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glyeol.
  • Compounds of Formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
  • the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15mg.
  • the daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg.
  • the daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.
  • the daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day.
  • the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • novel compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of CSBP/p38 or cytokine inhibition or production.
  • CSBP/p38 mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section, but in particular viral infections.
  • viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.
  • Interleukin - 1 D -1
  • Interleukin -8 IL-8
  • Tumour Necrosis Factor TNF
  • Interleukin - 1 (IL-1)
  • Human peripheral blood monocytes are isolated and purified from either fresh blood preparations from volunteer donors, or from blood bank buffy coats, according to the procedure of Colotta et al, J Immunol, 132, 936 (1984). These monocytes (1x10 ⁇ ) are plated in 24- well plates at a concentration of 1-2 million/ml per well. The cells are allowed to adhere for 2 hours, after which time non-adherent cells are removed by gentle washing. Test compounds are then added to the cells for lh before the addition of lipopolysaccharide (50 ng/ml), and the cultures are incubated at 37°C for an additional 24h. At the end of this period, culture supernatants are removed and clarified of cells and all debris.
  • IL- 1 biological activity either by the method of Simon et al, J. Immunol. Methods, 84, 85, (1985) (based on ability of IL-1 to stimulate a Interleukin 2 producing cell line (EL-4) to secrete IL-2, in concert with A23187 ionophore) or the method of Lee et al., J. ImmunoTherapy, 6 (1), 1-12 (1990) (ELISA assay).
  • Compounds of Formula (I), exemplified by Example 1 were found to be active in this assay having an IC50 of ⁇ 7uM.
  • mice and rats are injected with LPS.
  • mice from Charles River Laboratories are pretreated (30 minutes) with compound or vehicle. After the 30 min. pretreat time, the mice are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO) 25 ug/mouse in 25 ul phosphate buffered saline (pH 7.0) intraperitoneally. Two hours later the mice are killed by CO2 inhalation and blood samples are collected by exsanguination into heparinized blood collection tubes and stored on ice. The blood samples are centrifuged and the plasma collected and stored at -20°C until assayed for TNF ⁇ by ELISA.
  • LPS lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO
  • mice Male Lewis rats from Charles River Laboratories are pretreated at various times with compound or vehicle. After a determined pretreat time, the rats are given
  • LPS lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO
  • heparinized whole blood is collected from each rat by cardiac puncture 90 minutes after the LPS injection.
  • the blood samples are centrifuged and the plasma collected for analysis by ELISA for TNF ⁇ levels.
  • TNF ⁇ levels were measured using a sandwich ELISA, as described in Olivera et al., Circ. Shock, 37, 301-306, (1992), whose disclosure is inco ⁇ orated by reference in its entirety herein, using a hamster monoclonal antimurine TNF ⁇ (Genzyme, Boston, MA) as the capture antibody and a polyclonal rabbit antimurine TNFa (Genzyme) as the second antibody.
  • a peroxidase-conjugated goat antirabbit antibody Pierce, Rockford, IL
  • TNF ⁇ levels in the plasma samples from each animal were calculated from a standard curve generated with recombinant murine TNF ⁇ (Genzyme).
  • Test compound concentrations were prepared at 10 X concentrations and LPS prepared at 1 ug/ml (final cone, of 50 ng/ml LPS) and added in 50 uL volumes to 1.5 mL eppendorf tubes. Heparinized human whole blood was obtained from healthy volunteers and was dispensed into eppendorf tubes containing compounds and LPS in 0.4 mL volumes and the tubes incubated at 37 C. Following a 4 hour incubation, the tubes were centrifuged at 5000 ⁇ m for 5 minutes in a TOMY microfuge, plasma was withdrawn and frozen at -80 C.
  • Cytokine measurement IL-I and or TNF were quantified using a standardized ELISA technology. An in-house ELISA kit was used to detect human IL-1 and TNF. Concentrations of IL-1 or TNF were determined from standard curves of the appropriate cytokine and IC50 values for test compound (concentration that inhibited 50% of LPS-stimulated cytokine production) were calculated by linear regression analysis.
  • CSBP/p38 Kinase Assay This assay measures the CSBP/p38-catalyzed transfer of 32p from [a-
  • Reactions were carried in round bottom 96 well plate (from Corning) in a 30 ml volume. Reactions contained (in final concentration): 25 mM Hepes, pH 7.5; 8 mM MgCl2; 0.17 mM ATP (the KmrATP] of P 38 ( see Lee et al., Nature 300, n72 pg. 639-746 (Dec. 1994)); 2.5 uCi of [g-32P]ATP; 0.2 mM sodium orthovanadate; 1 mM DTT; 0.1% BSA; 10% glycerol; 0.67 mM T669 peptide; and 2-4 nM of yeast- expressed, activated and purified p38.
  • Reactions were initiated by the addition of [gamma-32P]Mg/ATP, and incubated for 25 min. at 37 °C. Inhibitors (dissolved in DMSO) were incubated with the reaction mixture on ice for 30 minutes prior to adding the 32P-ATP. Final DMSO concentration was 0.16%. Reactions were terminated by adding 10 ul of 0.3 M phosphoric acid, and phosphorylated peptide was isolated from the reactions by capturing it on p81 phosphocellulose filters. Filters were washed with 75 mM phosphoric acids, and inco ⁇ orated 32P was quantified using beta scintillation counter.
  • Example 2 demonstrated positive inhibitory activity of an IC50 of ⁇ 50uM in this binding assay or a similar assay.
  • Example 3 was found not to be active in this binding assay at concentrations of lOOuM.
  • This assay describes a method for determining the inhibitory effects of compounds of Formula (I) on human PGHS-2 protein expression in LPS stimulated human monocytes.
  • a suitable assay for PGHS-2 protein expression may be found in a number of publications, including US Patent 5,593,992 whose disclosure is inco ⁇ orated herein by reference.
  • This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- a is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- a plays an important role in both the acute and regenerative response to CNS trauma.
  • a suitable assay may be found in WO 97/35856 whose disclosure is inco ⁇ orated herein by reference.
  • This assay characterizes the regional expression of interleukin- l ⁇ (IL-l ⁇ ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-l ⁇ mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-1 ⁇ play a role in the post- traumatic pathologic or regenerative sequelae of brain injury.
  • TBI lateral fluid-percussion traumatic brain injury
  • Described in WO 97/32583 whose disclosure is inco ⁇ orated herein by reference, is an assay for determination of inflammatory angiogenesis which may be used to show that cytokine inhibition will stop the tissue destruction of excessive or inappropriate proliferation of blood vessels.
  • Example 1 1 -(Pyrid-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

Novel substituted triazole compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.

Description

NOVEL SUBSTITUTED TRIAZOLE COMPOUNDS
FIELD OF THE INVENTION
This invention relates to a novel group of triazole compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.
BACKGROUND OF THE INVENTION
Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phopholipases are the essential machinery by which the signal is further transmitted within the cell [Marshall, J. C. Cell , 80, 179-278 (1995)].
Protein kinases can be categorized into five classes with the two major classes being, tyrosine kinases and serine / threonine kinases depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine / threonine(s) residues [Hunter, T.. Methods in Enzymology ("Protein Kinase Classification) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991].
For most biological responses, multiple intracellular kinases are involved and an individual kinase can be involved in more than one signaling event. These kinases are often cytosolic and can translocate to the nucleus or the ribosomes where they can affect transcriptional and translational events, respectively. The involvement of kinases in transcriptional control is presently much better understood than their effect on translation as illustrated by the studies on growth factor induced signal transduction involving MAP/ERK kinase [Marshall, C. J. Cell . 80, 179 (1995); Herskowitz, I. Cell . 80, 187 (1995); Hunter, T. Cell . 80, 225 (1995);Seger, R., and Krebs, E. G. FASEB J.. 726-735 (1995)]. While many signaling pathways are part of cell homeostasis, numerous cytokines (e.g., IL-1 and TNF) and certain other mediators of inflammation (e.g., COX-2, and iNOS) are produced only as a response to stress signals such as bacterial lipopolysaccharide (LPS). The first indications suggesting that the signal transduction pathway leading to LPS-induced cytokine biosynthesis involved protein kinases came from studies of Weinstein [Weinstein, et al., J. Immunol. 151, 3829(1993)] but the specific protein kinases involved were not identified. Working from a similar perspective, Han [Han, et al, Science 265, 808(1994)] identified murine p38 as a kinase which is tyrosine phosphorylated in response to LPS. Definitive proof of the involvement of the p38 kinase in LPS-stimulated signal transduction pathway leading to the initiation of proinflammatory cytokine biosynthesis was provided by the independent discovery of p38 kinase by Lee [Lee; et al, Nature, 372, 739(1994)] as the molecular target for a novel class of anti-inflammatory agents. The discovery of p38 (termed by Lee as CSBP 1 and 2) provided a mechanism of action of a class of anti- inflammatory compounds for which SK&F 86002 was the prototypic example. These compounds inhibited IL- 1 and TNF synthesis in human monocytes at concentrations in the low uM range [Lee, et al., Int. J. Immunopharmac. 10(7), 835(1988)] and exhibited activity in animal models which are refractory to cyclooxygenase inhibitors [Lee; et al, Annals N. Y. Acad. Sci.. 696, 149(1993)].
MITOGEN AND STRESS ACTIVATED PROTEIN KINASE CASCADES
Figure imgf000004_0001
Figure 1
It is now firmly established that CSBP/p38 is a one of several kinases involved in a stress-response signal transduction pathway which is parallel to and largely independent of the analogous mitogen-activated protein kinase (MAP) kinase cascade (Figure 1). Stress signals, including LPS, pro-inflammatory cytokines, oxidants, UV light and osmotic stress, activate kinases upstream from CSBP/p38 which in turn phosphorylate CSBP/p38 at threonine 180 and tyrosine 182 resulting in CSBP/p38 activation. MAPKAP kinase-2 and MAPKAP kinase-3 have been identified as downstream substrates of CSBP/p38 which in turn phosphorylate heat shock protein Hsp 27 (Figure 2). It is not yet known whether MAPKAP-2, MAPKAP-3, Mnkl or Mnk2 are involved in cytokine biosynthesis or alternatively that inhibitors of CSBP/p38 kinase might regulate cytokine biosynthesis by blocking a yet unidentified substrate downstream from CSBP/p38 [Cohen, P. Trends Cell Biol.. 353-361(1997)].
p38 Kinase Pathway
LPS/IL-1/TNF stress/UV
Figure imgf000005_0001
Figure 2
What is known, however, is that in addition to inhibiting IL- 1 and TNF, CSBP/p38 kinase inhibitors (SK&F 86002 and SB 203580) also decrease the synthesis of a wide variety of pro-inflammatory proteins including, EL-6, IL-8, GM-CSF and COX-2. Inhibitors of CSBP/p38 kinase have also been shown to suppress the TNF- induced expression of VCAM-1 on endothelial cells, the TNF-induced phosphorylation and activation of cytosolic PLA2 and the EL- 1 -stimulated synthesis of collagenase and stromelysin. These and additional data demonstrate that CSBP/p38 is involved not only cytokine synthesis, but also in cytokine signaling [CSBP/P38 kinase reviewed in Cohen, P. Trends Cell Biol., 353-361(1997)].
Interleukin-1 (IL-1) and Tumor Necrosis Factor (TNF) are biological substances produced by a variety of cells, such as monocytes or macrophages. DL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984)]. The myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.
There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease; tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis, and acute synovitis. Recent evidence also links IL-1 activity to diabetes and pancreatic β cells [review of the biological activities which have been attributed to IL-1 Dinarello, J. Clinical Immunology. 5 (5), 287-297 (1985)].
Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
Interleukin-8 (EL-8) is a chemotactic factor produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, and keratinocytes. Its production from endothelial cells is induced by IL-1, TNF, or lipopolysachharide (LPS). IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysozomal enzyme release and respiratory burst from neutrophils. IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis, this may contribute to increased adhesion of the neutrophils to vascular endothelial cells. Many diseases are characterized by massive neutrophil infiltration. Conditions associated with an increased in IL-8 production (which is responsible for chemotaxis of neutrophil into the inflammatory site) would benefit by compounds which are suppressive of IL-8 production. IL-1 and TNF affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
Inhibition of signal transduction via CSBP/p38, which in addition to IL-1, TNF and IL-8 described above is also required for the synthesis and/or action of several additional pro-inflammatory proteins (i.e., IL-6, GM-CSF, COX-2, collagenase and stromelysin), is expected to be a highly effective mechanism for regulating the excessive and destructive activation of the immune system. This expectation is supported by the potent and diverse anti-inflammatory activities described for CSBP/p38 kinase inhibitors [Badger, et al, J. Pharm. Exp. Thera. 279 (3): 1453- 1461.(1996); Griswold, et al, Pharmacol. Comm. 7, 323-229 (1996)].
There remains a need for treatment, in this field, for compounds which are cytokine suppressive anti-inflammatory drugs, i.e. compounds which are capable of inhibiting the CSBP/p38 RK kinase.
SUMMARY OF THE INVENTION
This invention relates to the novel compounds of Formula (I), (II) and (III) and pharmaceutical compositions comprising a compound of Formula (I), (II) or
(III) and a pharmaceutically acceptable diluent or carrier. This invention relates to a method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (III). This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of
Formula (I), (II) or (III). This invention more specifically relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (HI).
This invention more specifically relates to a method of inhibiting the production of IL-6 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (III).
This invention more specifically relates to a method of inhibiting the production of EL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II) or (III). This invention more specifically relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I), (II), or (III).
Accordingly, the present invention provides a compound of Formula (I):
Figure imgf000008_0001
wherein
Rl is pyrid-4-yl, or pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, Ci-4 alkyl, halogen, hydroxyl, Cι_4 alkoxy, Ci-4 alkylthio, Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, or a N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or
NRl5, or N(Rio)C(O)Rb; Y is Xι-Ra;
X1 is sulfur, oxygen, or NH;
Ra is Ci-6alkyl, aryl, arylCi-όalkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylC 1 _6alkyl; and wherein each of these moieties may be optionally substituted; R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri7, C(Z)ORi6,
(CRioR20)vCORi2, SR5, SOR5, OR12, halo-substituted-Ci-4 alkyl, C alkyl, ZC(Z)Ri2, NRιoC(Z)Ri6, or (CRifjR2θ)vNRioR20 and which, for other positions of substitution, is halogen, cyano, C(Z)NRi3R]4, C(Z)OR3, (CRioR20)m"COR3, S(O)mR3, OR3, halo-substituted-Cι.4 alkyl, Ci-4 alkyl, (CRioR2θ)m"NRlθC(Z)R3, NRι0S(O)m-R8, NRioS(O)m'NR7Ri7, ZC(Z)R3 or (CRioR20)m"NRl3Rl4;
Z is oxygen or sulfur; n is 0, or an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2;
R2 is hydrogen, C(H)(A)(R22), (CRlθR23)n OR9, (CRιoR23)nOR_ l, Ci-ioalkyl, halo-substituted -io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl,
C3-7cycloalkylCi-io alkyl, C5.7 cycloalkenyl, C5.7 cycloalkenyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-ioalkyl, heterocyclyl, heterocyclylCi-io alkyl, (CRi0R23)nS(O)mRi8, (CRιoR23)nNHS(O)2Rl8, (CRlθR23)nNRi3Rl4, (CRιoR23)nNO2, (CRι0R23)nCN, (CRιoR23)nS(O)m'NRι3Rι4, (CRioR230)nC(Z)Rn, (CRi0R23)nOC(Z)Rn, (CRioR23)nC(Z)ORn,
(CRιoR23)nC(Z)NRι3Rl4, (CRι0R23)nC(Z)NRι 1OR9, (CRιoR23)nNRιoC(Z)Rι ι, (CRlθR23)nNRioC(Z)NRι3Rl4, (CRiθR23)nN(OR6)C(Z)NRι3Rl4, (CRι0R23)nN(OR6)C(Z)Rι i,
Figure imgf000009_0001
(CRιoR23)nOC(Z)NRi3Rl4, (CRιoR23)nNRiθC(Z)NRi3Ri4,
(CR 10R23)nNR 1 oC(Z)OR 10, 5-(R 18)- 1 ,2,4-oxadizaol-3-yl or 4-(R 12)-5- (Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; and wherein the cycloalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl groups may be optionally substituted; A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted C 1-10 alkyl;
R22 is an optionally substituted Cι_ιo alkyl;
Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCj-4 alkyl; and wherein each of these moieties may be optionally substituted;
R3 is heterocyclyl, heterocyclylCi-io alkyl or R$; R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH; R is hydrogen, a pharmaceutically acceptable cation, C -io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl; R7 and R17 is each independently selected from hydrogen or Ci-4 alkyl or R7 and Rl7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; R8 is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CRioR20)nORl l, (CRιoR2θ)nS(O)mRi8, (CRι0R20)nNHS(O)2Rl8, or (CRioR20)nNRi3Rl4; and wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl may be optionally substituted; R9 is hydrogen, C(Z)Rπ or optionally substituted Ci-io alkyl, S(O)2Rl8, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl; RlO and R20 are each independently selected from hydrogen or C 1.4 alkyl; Rl 1 is hydrogen, Ci-io alkyl, C3.7 cycloalkyl, heterocyclyl, heterocyclyl
Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylCi-io alkyl, wherein these moieties may be optionally substituted;
Rl2 is hydrogen or Ri6;
Rl3 and R14 is each independently selected from hydrogen or optionally substituted Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9;
Rl5 is Rio or C(Z)-Cι_4 alkyl;
Rl6 is Cj-4 alkyl, halo-substituted-Cι.4 alkyl, or C3-7 cycloalkyl; Rl8 is Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Cj- ioalkyl, heteroaryl or heteroaryl i-ioalkyl;
Rl9 is hydrogen, cyano, C1.4 alkyl, C3-7 cycloalkyl or aryl; R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCj-4 alkyl moiety, all of which may be optionally substituted; or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
Another aspect of the present invention are the novel compounds of Formula (II) represented by the structure: Accordingly, the present invention provides for a compound of Formula (II):
Figure imgf000011_0001
wherein
Rl is a pyrid-4-yl, or pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, Ci-4 alkyl, halogen, hydroxyl, Ci-4 alkoxy, Ci-4alkylthio,
Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, or a N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or
Figure imgf000011_0002
Y is Xι-Ra;
X is sulfur, oxygen, or NH;
Ra is Cι_6alkyl, aryl, arylCj-όalkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylCι_6alkyl, wherein each of these moieties may be optionally substituted; R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri7, C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR12, halo-substituted-Ci-4 alkyl, -4 alkyl, ZC(Z)Ri2, NRιoC(Z)Ri6, or (CRιoR2θ)vNRlθR20 and which, for other positions of substitution, is halogen, cyano, C(Z)NRi3Ri4, C(Z)OR3, (CRioR20)m"COR3, S(O)mR3, OR3, halo-substituted-Ci-4 alkyl, Ci-4 alkyl, (CRiθR2θ)m"NRlθC(Z)R3, NRi0S(O)m'R8, NRι0S(O)m'NR7Rl7, ZC(Z)R3 or (CRi0R20)m"NRl3Rl4; Z is oxygen or sulfur; n is 0, or an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2;
R2 is hydrogen, C(H)(A)(R22), (CRlθR23)n OR9, (CRιoR23)nORn, Ci-ioalkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl, C3-7cycloalkylCi-io alkyl, C5.7 cycloalkenyl, C5-7 cycloalkenyl -ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-ioalkyl, heterocyclyl, heterocyclylCi-io alkyl, (CRi0R23)nS(O)mRi8, (CRι0R23)nNHS(O)2Rl8, (CRlθR23)nNRi3Rl4, (CRιoR23)nNO2, (CRι0R23)nCN, (CRιoR23)nS(O)m'NRι3Rl4, (CRioR230)nC(Z)Rn, (CRιoR23)nOC(Z)Rn, (CRi0R23)nC(Z)ORn, (CRi0R23)nC(Z)NRi3Rl4, (CRi0R23)nC(Z)NRι 1OR9, (CRιoR23)nNRlθC(Z)Rn, (CRιoR23)nNRlθC(Z)NRi3Rl4,
(CRιoR23)nN(OR6)C(Z)NRι3Ri4, (CRι0R23)nN(OR6)C(Z)Rι 1, (CRioR23)rA=NOR6)Rl 1, (CRιoR23)nNRiθC(=NRι9)NRι3Rl4, (CRιoR23)nOC(Z)NRι3Ri4, (CRιoR23)nNRlθC(Z)NRi3Rl4, (CRιoR23)nNRlθC(Z)ORιo, 5-(Ri8)-l,2,4-oxadizaol-3-yl or 4-(Rι2)-5- (Ri8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; wherein the cycloalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl groups may be optionally substituted;
A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted Cl-10 alkyl; R22 is an optionally substituted C J. IQ alkyl;
Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; and wherein each of these moieties may be optionally substituted; R3 is heterocyclyl, heterocyclylCi-io alkyl or Rs; R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH; R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3.7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci- o alkanoyl; R7 and R 7 is each independently selected from hydrogen or C 1.4 alkyl or R7 and
Rl7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15;
R8 is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CRι0R20)nORi 1, (CRιoR2θ)nS(O)mRi8, (CRioR2θ)nNHS(O)2Rl8, (CRioR20)nNRl3Rl4; and wherein the aryl, arylalkyl, heteroaryl, and heteroarylalkyl moieties may be optionally substituted; R9 is hydrogen, C(Z)Rι 1 or optionally substituted -io alkyl, S(O)2Rl8, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl;
RlO and R20 are each independently selected from hydrogen or C _4 alkyl; Rl 1 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl
Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylCi-io alkyl, wherein all of these moieties may be optionally substituted; Rl2 is hydrogen or Ri6; R13 and R14 is each independently selected from hydrogen or optionally substituted C -4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9 ; Ri5 is Rιo or C(Z)-Ci-4 alkyl;
Rl6 is Ci-4 alkyl, halo-substituted-Ci-4 alkyl, or C3-7 cycloalkyl;
Rl8 is Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroaryl i-ioalkyl; R 9 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl or aryl; R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety, all of which may be optionally substituted; or a pharmaceutically acceptable salt thereof.
Another aspect of the present invention are the novel compounds of Formula (III) represented by the structure:
Accordingly, the present invention provides for a compound of Formula
Figure imgf000013_0001
wherein Rl is a pyrid-4-yl, or a pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, Cι_4 alkyl, halogen, hydroxyl, Cj-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, a N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NRi5, or N(Rιo)C(O)RD;
Y is Xι-Ra; X is sulfur, oxygen or NH; Ra is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylC _6alkyl, wherein each of these moieties may be optionally substituted; R4 is a phenyl, naphth-1-yl, naphth-2-yl, or a heteroaryl ring, which rings are optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2- yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri7, C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR12, halo-substituted-Ci-4 alkyl, Ci-4alkyl, ZC(Z)Ri2, NRιoC(Z)Ri6, or (CRioR20)vNRioR20 and which, for other positions of substitution, is halogen, cyano, C(Z)NRi3Ri4, C(Z)OR3,
(CRioR20)m"COR3, S(O)mR3, OR3, halo-substituted-Ci-4 alkyl, Cι_4 alkyl, (CRιoR2θ)m"NRlθC(Z)R , NRιoS(O)m'R8, NRιoS(O)m'NR7Rl7, ZC(Z)R3 or (CRioR20)m"NRi3Rl4; Z is oxygen or sulfur; n is 0, or an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2; R2 is hydrogen, C(H)(A)(R22), (CRlθR23)n OR9, (CRιoR23)nOR_ 1, Ci-ioalkyl, halo-substituted -io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylCi-io alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl Cμioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-ioalkyl, heterocyclyl, heterocyclylCj- o alkyl, (CRιoR23)nS(O)mRi8, (CRι0R23)nNHS(O)2Rl8, (CRioR23)nNRi3Rl4, (CRlθR23)nNO2, (CRiθR23)nCN, (CRioR23)nS(O)m'NRι3Rι4,
(CRioR230)nC(Z)Ri 1, (CRιoR23)nOC(Z)Rι 1, (CRι0R23)nC(Z)ORι 1, (CRιoR23)nC(Z)NRι3Rl4, (CRι0R23)nC(Z)NRι 1OR9, (CRioR23)nNRlθC(Z)Rn, (CRιoR23)nNRioC(Z)NRi3Rl4, (CRioR23)nN(OR6)C(Z)NRi3Rl4, (CRi0R23)nN(OR6)C(Z)Rι i, (CRioR23)nC(=NOR6)Rl l, (CRιoR23)nNRlθC(=NRι9)NRι3Rl4,
(CRlθR23)nOC(Z)NRi3Rl4, (CRlθR23)nNRiθC(Z)NRι3Rl4, (CRιoR23)nNRlθC(Z)ORιo, 5-(Ri8)-l,2,4-oxadizaol-3-yl or 4-(Ri2)-5-(Ri8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; wherein the cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic and heterocyclicalkyl groups may be optionally substituted; A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted Ci-io alkyl;
R22 is an optionally substituted C _ιo alkyl;
R is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; and wherein each of these moieties may be optionally substituted; R3 is heterocyclyl, heterocyclylC -io alkyl or Rs; R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH; R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl; R7 and R 7 is each independently selected from hydrogen or Cj-4 alkyl or R7 and Rl7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; R8 is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-10 alkyl, (CRioR20)nOR_ l, (CRιoR2θ)nS(O)mRi8, (CRioR20)nNHS(O)2Rl8. (CRιoR2θ)nNRl3Rl4; and wherein the aryl, arylalkyl, heteroaryl, and heteroarylalkyl moieties may be optionally substituted; R9 is hydrogen, C(Z)Rι 1 or optionally substituted Ci-io alkyl, S(O)2Rl8. optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl; RlO and R20 are each independently selected from hydrogen or Ci-4 alkyl; Ri is hydrogen, - o alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl
Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylCi-io alkyl, wherein all of these moieites may be optionally substituted; Rl2 is hydrogen or R 6;
Rl3 and R14 is each independently selected from hydrogen or optionally substituted Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; Rl5 is Rio or C(Z)-Cι_4 alkyl; R 16 is C 1 -4 alkyl, halo-substituted-C 1.4 alkyl, or C3-7 cycloalkyl; Rl8 is Ci-10 alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci- oalkyl, heteroaryl or heteroaryl i-ioalkyl; Rl9 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl or aryl; R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCj-4 alkyl moiety, all of which may be optionally substituted; or a pharmaceutically acceptable salt thereof.
It is recognized that for compounds of Formula (I), (II) and (III), the R1 , R2 and R4 moieties are the same. Suitable Rl moieties for use herein include a 4-pyridyl, or 4-pyrimidinyl ring. More preferred is the 4-pyrimdinyl ring.
The Ri moiety is optionally substituted one or more times, suitably 1 to 3 times, with Y, optionally substituted C -4 alkyl, halogen, hydroxyl, optionally substituted C _4alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(Rιo)C(O)Rb, N(Rιo)S(O)2Rd» or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NRi5.
Suitably Y is Xι-Ra; and X is oxygen, sulfur or nitrogen, preferably oxygen.
Suitably Ra is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylCι_6alkyl, wherein each of these moieties may be optionally substituted as defined herein.
When Ra is aryl, it is preferably phenyl or napthyl. When Ra is arylalkyl, it is preferably benzyl or napthylmethyl. When Ra is a heterocyclic or heterocyclic alkyl moiety, the heterocyclic portion is preferably pyrrolindinyl, piperidinyl, morpholino, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothipyransulfinyl, tetrahydrothio-pyransulfonyl, pyrrolindinyl, indole, or piperonyl ring. It is noted that the heterocyclic rings herein may contain unsaturation, such as in a tryptamine ring.
When Ra is a heteroaryl ring as defined below, it is preferably a pyridine or tetrazole ring.
The Ra aryl, heterocyclic and heteroaryl rings may be optionally substituted one or more times, preferably one to three times, independently with halogen; Ci-4 alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; halosubstituted alkyl, such as CF3; hydroxy; hydroxy substituted C -4 alkyl; (CR 0R20) _ l-4 alkoxy, such as methoxy or ethoxy; (CR QR20)C1 S(O)malkyl and (CR10R20) -S(O)m aryl (wherein m is 0, 1, or 2); (CRιoR2θ)qc(O)ORι 1, such as C(O)Ci-4 alkyl or C(O)OH moieties; (CRιoR2θ)qc(°)Rl i ; (CRιoR2θ)q° (O)Rc; O-(CH2)s-O; (CR10R2θ)q Rl3 l4; ( Rlθ 2θ) (Rlθ)C(O)Rb; (CRιoR2θ)qC(O)NRi Ri4; (CR1oR20)qC(O)NR10Rc; (CRioR20)qS(O)2NRi3Rl4; (CR10R2θ)qS(O)2NR10Rc; (CRι0R2θ) N(Rlθ)S(O)2Rc; cyano, nitro, an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; aryl, such as phenyl; an optionally substituted arylalkyl, such as benzyl or phenethyl; aryloxy, such as phenoxy; or arylalkyloxy such as benzyloxy; and wherein the aryl, alkylalkyl, aryloxy and arylalkyloxy containing moieties may be optionally substituted themselves one to two times by halogen, hydroxy, hydroxy substituted alkyl, Ci-io alkoxy, S(O)m alkyl, amino, NR7R17 group, C1.4 alkyl, or halosubstituted Cj_4 alkyl.
Suitably, s is an integer having a value of 1, 2, or 3. Preferably s is 2 yielding a 1 ,3-dioxyethylene moiety, or ketal functionality.
Suitably, q is 0 or an integer having a value of 1 to 4. Suitably, Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety; all of which moieties may be optionally substituted as defined below.
Suitably, Rc is an -6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety, all of which moieties may be optionally substituted as defined below.
When the Ra moiety is an alkyl group it may be optionally substituted as defined herein in the definition section below. Also, the alkyl portion of the R substituents, where applicable, such as the mono- and di-C -6 alkyl amino moieties, may be halo substituted. Preferred Ra groups include, methyl, ethyl, benzyl, halosubstituted benzyl, napthylmethyl, phenyl, halosubstituted phenyl, aminocarbonylphenyl, alkylphenyl, cyanophenyl, alkylthiophenyl, hydroxyphenyl, alkoxyphenyl, phenoxyphenyl, benzyloxyphenyl, phenylphenyl, methylenedioxyphenyl, trifluoromethylphenyl, methylsulfonylphenyl, tetrazole, methyltetrazolyl, morpholinopropyl, piperonyl, piperidin-4-yl, alkyl substituted piperidine, such as 1 -methyl piperidine, or 2,2,6,6- tetramethylpiperidin-4-yl .
Preferred ring substitution on the benzyl or phenyl rings is in the 4-position. Preferred substitution on the phenyl or phenyl alkyl groups is halogen, halosubstituted alkyl or alkyl groups, such as fluoro or chloro, or methyl. When the additional Rl optional substituent is N(Rιo)C(O)Rb, Rb is preferably Ci-6 alkyl; preferably Rio is hydrogen. It is also recognized that the Rb moieties, in particular the Ci-6 alkyl group may be optionally substituted, preferably from one to three times, preferably with halogen, such as fluorine, as in trifluoro- methyl or trifluroethyl.
The preferred ring placement for the optional substituents on the 4-pyridyl derivative is in the 2-position, and a preferred ring placement on the 4-pyrimidinyl ring is also at the 2-position. A preferred substituent group is methoxy.
Suitably, R4 is a phenyl, naphth-1-yl, naphth-2-yl, or a heteroaryl ring, all of which rings may be optionally substituted, independently, by one or two substituents. More preferably R4 is a phenyl or naphthyl ring. Suitable substitutions for R4 when this is a 4-phenyl, 4-naphth-l-yl,
5-naphth-2-yl or 6-naphth-2-yl moiety are one or two substituents each of which are independently selected from halogen, SR5, SOR5, OR12, CF3, or (CR oR2θ)vNRlθR20» and for other positions of substitution on these rings preferred substitution is halogen, S(O)mR3, OR3, CF3, (CRioR20)m"NRi3Ri4, NRioC(Z)R3 and NRιoS(O)m'R8.
When R4 is a heteroaryl ring, the ring is substituted in a similar ring substitution pattern as for the phenyl ring as described above,. Preferably, halogen, SR5, SOR5, OR 12, CF3, or (CRιoR2θ)vNRlθR20.
Preferred substituents for the 4-position in phenyl and naphth-1-yl and on the 5-position in naphth-2-yl include halogen, especially fluoro and chloro and SR5 and SOR5 wherein R5 is preferably a Ci-2 alkyl, more preferably methyl; of which the fluoro and chloro is more preferred, and most especially preferred is fluoro.
Preferred substituents for the 3-position in phenyl and naphth-1-yl rings include: halogen, especially fluoro and chloro; OR3, especially Ci-4 alkoxy; CF3, NR10R2O. such as amino; NRioC(Z)R3, especially NHCO(Ci-io alkyl);
NRιoS(O)m'R8, especially NHSO2(CMO alkyl), and SR3 and SOR3 wherein R3 is preferably a Ci-2 alkyl, more preferably methyl. When the phenyl ring is disubstituted preferably it is two independent halogen moieties, such as fluoro and chloro, preferably di-chloro and more preferably in the 3, 4-position. It is also preferred that for the 3-position of both the OR3 and ZC(Z)R3 moieties, R3 may also include hydrogen.
Preferably, the R4 moiety is an unsubstituted or substituted phenyl moiety. More preferably, R4 is phenyl or phenyl substituted at the 4-position with fluoro and/or substituted at the 3-position with fluoro, chloro, Ci-4 alkoxy, methane- sulfonamido or acetamido, or R4 is a phenyl di-substituted at the 3,4-position independently with chloro or fluoro, more preferably chloro. Most preferably, R4 is a 4-fluorophenyl.
Suitably, Z is oxygen or sulfur, preferably oxygen.
Suitably, R3 is heterocyclyl, heterocyclylCi-io alkyl or Rg. Suitably, R5 is hydrogen, Cμ4 alkyl, C2-4 alkenyl, C2-4 alkynyl or
NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH.
Suitably, R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, aroyl, or Ci-io alkanoyl. Suitably, R7 and R17 is each independently selected from hydrogen or Cl-4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15.
Suitably, Rs is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-IO alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CRιoR20)nORl l, (CRιoR2θ)nS(O)mRi8, (CRioR20)nNHS(O)2Rl8, or CRioR20)nNRl3Rl4; wherein the aryl, arylalkyl, heteroaryl, and heteroarylalkyl containing moieties may be optionally substituted.
Suitably, R9 is hydrogen, C(Z)Rι 1, optionally substituted Ci-io alkyl, S(O)2Rl8» optionally substituted aryl or an optionally substituted aryl-Ci-4 alkyl.
Suitably, Rio and R20 are each independently selected from hydrogen or C 1-4 alkyl.
Suitably, Rl 1 is hydrogen, -io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylCi-io alkyl; and wherein all of these moieties may be optionally substituted.
Suitably, R12 is hydrogen or Ri6; and Rl6 i suitably, C1.4 alkyl, halo- substituted-Ci-4 alkyl, or C3-7 cycloalkyl.
Suitably, R13 and R14 is each independently selected from hydrogen or optionally substituted Cj-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9.
Suitably, R15 is Rio or C(Z)-Ci-4 alkyl.
Suitably, Ri8 is Ci-io alkyl, C3.7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroaryl -ioalkyl. Suitably, v is 0, or an integer having a value of 1 or 2.
Suitably, m is 0, or the integer 1 or 2.
Suitably, m' is an integer having a value of 1 or 2.
Suitably, m" is 0, or an integer having a value of 1 to 5. Suitably, n is an integer having a value of 1 to 10.
Suitably, R2 is hydrogen, C(H)(A)(R22), (CRlθR23)n OR9, (CRιoR23)nORl l, Ci-ioalkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3.7 cycloalkyl, C3.7cycloalkylC1.io alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-ioalkyl, heterocyclyl, heterocyclylCi-io alkyl, (CRιoR23)nS(O)mRl8,
(CRlθR23)nNHS(O)2Rl8, (CRioR23)nNRl3 l4, (CRlθR23)nNO2) (CRι0R23)nCN, (CRιoR23)nS(O)m'NRι3Ri4, (CRioR230)nC(Z)Rn, (CRιoR23)nOC(Z)Rn, (CRι0R23)nC(Z)ORn, (CRι0R23)nC(Z)NRι3Rl4, (CRιoR23)nC(Z)NRnOR9, (CRιoR23)nNRlθC(Z)Rι ι, (CRιoR23)nNRlθC(Z)NRi3Rl4, (CRι0R23)nN(OR6)C(Z)NRι3Ri4, (CRi0R23)nN(OR6)C(Z)Ri i, (CRi0R23)nC(=NOR6)Rl 1,
(CRιoR23)nNRlθC(=NRi9)NRι3Rl4, (CRiθR23)nOC(Z)NRi3Rl4, (CRι0R23)nNRlθC(Z)NRi3Rl4, (CRlθR23)nNRioC(Z)ORιo, 5-(Ri8)-l,2,4- oxadizaol-3-yl or 4-(Ri2)-5-(Ri8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; wherein the cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl groups may be optionally substituted.
Suitably, R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or a heterocyclylCi-4 alkyl moiety, all of which moieties may be optionally substituted as defined below. Preferably, R2 is hydrogen, C(H)(A)(R22)> an optionally substituted heterocyclyl ring, and optionally substituted heterocyclylCi-io alkyl, an optionally substituted Ci-io alkyl, an optionally substituted C3_7cycloalkyl, an optionally substituted C3-7cycloalkyl -io alkyl, (CRιoR23)nC(Z)ORn group,
(CRιoR23)nNRl3Rl4, (CRioR23)nNHS(O)2Rl8, (CRlθR23)nS(O)mRι8, an optionally substituted aryl; an optionally substituted arylCi-io alkyl,
(CRιoR23)nORπ, (CRιoR23)nC(Z)Rn, or (CRι0R23)nC (=NOR6)Rl l group. Suitably when R2 is C(H)(A)(R22) it is recognized that the first methylene carbon in this chain is a tertiary carbon, and it will contain one hydrogen moiety. This methylene group will have has two additional substituents, an R22 moiety and an A moiety, i.e., C(H)(A)(R22)- In a preferred embodiment, R2 is a C(AA )(A) moiety, wherein AA is the R22 moiety, but is specifically the side chain residue (R) of an amino acid, as is further described herein.
Suitably, A is an optionally substituted C3-7cycloalkyl, aryl, heteroaryl, or heterocyclic ring, or A is a substituted CJ.JO alkyl moiety.
When A is an aryl, heteroaryl and heterocyclic ring, the ring may be substituted independently one or more times, preferably, 1 to 3 times by Ci-io alkyl; halogen; halo substituted -io alkyl, such as CF3; (CRιoR2θ)tORl l; (CRιoR2θ)tNRl3Rl4, especially amino or mono- or i-C .4 alkylamino; (CRioR2θ)tS(O)mRl8> wherein m is 0, 1 or 2; SH; NRιo Z)R3 (such NHCO(CMO alkyl)); or NRιoS(O)mR8 (such as NHSO2(Ci-io alkyl)).
Suitably, t is 0, or an integer of 1 to 4.
When A is an optionally substituted cycloalkyl it is as defined below in the R22 substitution. When A is an optionally substituted heterocyclyl ring, the ring is preferably a morpholino, pyrrolidinyl, piperazinyl or a piperidinyl ring.
When A is an optionally substituted aryl moiety, it is preferably a phenyl ring.
When A is an optionally substituted heteroaryl ring, the heteroaryl term is as defined below in the definition section. When A is a substituted \.\Q alkyl moiety, the alkyl chain may be straight or branched. The chain is substituted independently 1 or more times, preferably 1 to 3 times by halogen, such as fluorine, chlorine, bromine or iodine; halosubstituted Ci-io alkyl, such as CF3; C3-7cycloalkyl, Ci-io alkoxy, such as methoxy or ethoxy; hydroxy substituted C -io alkoxy; halosubstituted Cj-io alkoxy, such as OCF2CF2H; ORπ; S(O)mRi8 (wherein m is 0, 1 or 2); NR13R14; C(Z)NRi3Ri4;
S(O)m'NRi3Rl4; NR23C(Z)Ri i; NHS(O)2Rl8; C(Z)Rι ι; OC(Z)Rn; C(Z)ORι i;
C(Z)NRι 1OR9; N(OR6)C(Z)NRi3Rl4; N(OR6)C(Z)Rι i; C(=NOR6)Rl l;
NR23C(=NRi9)NRi3Ri4; OC(Z)NRι3Rι4; NR23C(Z)NRι3Rι4; or
Figure imgf000021_0001
Preferably, A is a C3.7 cycloalkyl, or a C j.g alkyl, more preferably a Cj_2 alkyl, i.e. a methylene or ethylene moiety, more preferably a methylene moiety which is substituted by one of the above noted groups.
Preferably, when A is an alkyl derivative, it is substituted by ORj \ where R 1 is preferably hydrogen, aryl or arylalkyl; NR13R14; OC(Z)Rι 1; or C(Z)ORι 1- More preferably, A is substituted by R\ \ where Rj j is hydrogen. Suitably, R22 i a CJ.IQ alkyl chain, which chain may be straight or branched and which may be optionally substituted independently, one or more times, preferably 1 to 3 times, by halogen, such as fluorine, chlorine, bromine or iodine; halo substituted Ci-io alkyl; Ci-io alkoxy, such as methoxy or ethoxy; hydroxy substituted Ci-io alkoxy; halosubstituted -io alkoxy, such as OCF2CF2H; ORi 1 ; S(O)mRi8;
NR13R14; C(Z)NRi3Rl4; S(O)m'NRι3Rl4; NR23C(Z)Rn; NHS(O)2Rl8J C(Z)Rn; OC(Z)Rn; C(Z)ORπ; C(Z)NRnOR9; N(OR6)C(Z)NRι3Rι4;
N(OR6)C(Z)Rn; C(=NOR6)Rl i; NR23C(=NRι9)NRι3Rl4; OC(Z)NRι3Rl4; NR23C(Z)NRi3Ri4; NR23C(Z)ORιo; optionally substituted C3.7 cycloalkyl; optionally substituted aryl, such as phenyl; optionally substituted heteroaryl; or an optionally substituted heterocyclic moiety. The optional substituents on these cycloalkyl, aryl, heteroaryl, and heterocyclic moieties are as defined herein below. It is noted that those R22 substituent groups which contain carbon as the first connecting group, i.e. C(Z)ORi 1; C(Z)NRι ιOR9( C(Z)Ri 1, C(Z)NRi3Ri4,
Figure imgf000022_0001
1, may be the sole carbon in alkyl chain. Therefore, R22 may, for instance, be a carboxy, an aldehyde, an amide, as well as being a substituent off a methylene unit, such as carbamoylmethyl, or acetamidomethyl. In other words, R22 can be an optionally substituted alkyl group as defined above, or R22 can be C(Z)OR 11 , C(Z)NR 11 OR9, C(Z)R 11 , C(Z)NR 13R 14, or C(=NOR6)R 11. Preferably R22 is a C g unsubstituted or substituted alkyl group, such as a C 1.3 alkylene, such as methyl, ethyl or isopropyl, or a methylene or ethylene moiety substituted by one of the above noted moieties, or as noted above those substituent groups which contain a carbon may substituent for the first methylene unit of the alkyl chain, such as carboxy, C(O)OR j, C(O)NRi3Ri4, or R22 i an optionally substituted aryl group, such as a benzyl or phenethyl.
Preferably R22 is a C|_6 unsubstituted or substituted alkyl group, more preferably a Cj_2 alkylene chain, such as a methylene or ethylene moiety, more preferably methylene.
Preferably the R22 alkyl chain is substituted by ORj \, where Rl 1 is preferably hydrogen, aryl or arylalkyl; S(O)mRi8, where m is 0 and R\% is a Cj.g alkyl; or an optionally substituted aryl, i.e. a benzyl or phenethyl moiety.
More preferably, R22 i methyl, phenyl, benzyl, CH2OH, or CH2-O-aryl.
Preferably, one or both of A and R22 contain hydroxy moieties, such as in C \.^ alkyl ORj j, wherein Ri 1 is hydrogen, i.e.CH2CH2OH. Suitably, when AAj is the (R) side chain residue of an amino acid, it is a C j_ 5 alkyl group, which may be straight or branched. This means the R group off the core amino acid of the structure R-C(H)(COOH)(NH2). The R residue term is for example, CH3 for alanine, (CI^CH- for valine, (CH3)2CH-CH2-for leucine, phenyl-CH2- for phenylalanine, CH3-S-CH2-CH2- for methionine, etc. All generally recognized primary amino acids are included in this groups, such as but not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, hydroxylysine, methylhistidine, and other naturally occurring amino acids not found in proteins, such as b-alanine, g-aminobutyric acid, homocysteine, homoserine, citrulline, ornithine, canavanine, djenkolic acid, and b-cyanoalanine, or other naturally occurring non-mammalian amino acids.
Preferably AAj is the residue of phenylalanine, or alanine.
When R22 is an optionally substituted heterocyclic moiety, the ring is preferably a morpholino, pyrrolidinyl, piperazinyl, or a piperidinyl group. When the heterocyclic ring is optionally substituted the substituents may be directly attached to the free nitrogen, such as in the piperidinyl group or pyrrole ring, or on the ring itself.
Preferably the ring is a piperidine or pyrrole, more preferably piperidine.
The R22 heterocyclyl ring may be optionally substituted one to four times independently by halogen; Ci-4 alkyl; aryl, such as phenyl; arylalkyl, such as benzyl,
(and wherein the aryl or aryl alkyl moieties themselves may be optionally substituted as defined in the definition section below); C(O)ORι 1, such as the C(O)Cι_4 alkyl or C(O)OH moieties; C(O)H; C(O)Ci-4 alkyl; hydroxy substituted Ci-4 alkyl; C1.4 alkoxy; S(O)mCi-4 alkyl (wherein m is 0, 1, or 2); or NR10R2O (wherein Rio and R20 are independently hydrogen or Ci-4alkyl).
Preferably if the ring is a piperidine, the substituents are attached directly on the available nitrogen, i.e. a l-Formyl-4-piperidine, l-benzyl-4-piperidine, l-methyl-4- piperidine, l-ethoxycarbonyl-4-piperidine. If the ring is substituted by an alkyl group and the ring is attached in the 4-position, it is preferably substituted in the 2- or 6- position or both, such as 2,2,6,6-tetramethyl-4-piperidine. Similarly, if the ring is a pyrrole, the substituents are all directly on the available nitrogen. When the R22 optional substituent is an optionally substituted aryl, it is preferably a phenyl; or when R22 i an optionally substituted heteroaryl ring (as defined in the definition section below), the rings may be optionally substituted independently one or more times, preferably by one to three times by Ci- o alkyl; halogen, especially fluoro or chloro; (CRioR20)tORl 1; (CR oR2θ)t Ri3Ri4; especially amino or mono- or di-Cι.4 alkylamino; (CRioR2θ)tS(O)mRl8. wherein m is 0, 1 or 2; SH; ORi 1 ; NRioC(Z)R3 (such NHCO(Ci-io alkyl)); or NRioS(O)mR8 (such as NHSO2(Ci-io alkyl)).
When A or R22 is an (optionally) substituted C3-7cycloalkyl group, it is preferably a C3 or C6 ring, most preferably a C3 ring, which ring may be optionally substituted one or more time, preferably 1 to 3 times, independently by halogen, such as fluorine, or chlorine; (CRioR20)tORn; S(O)mRi8; cyano; (CRιoR2θ)t Rl3Rl4; especially amino or mono- or di-Cι.4 alkylamino; N(Rιo)C(O)Xι and Xi is Ci-4 alkyl, aryl or arylCi-4alkyl; Ci-io alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl; an optionally substituted alkyl wherein the substituents are halogen, (such as CF3), hydroxy, nitro, cyano, amino, NR13R14, or S(O)mR ; an optionally substituted alkylene, such as ethylene or propylene; an optionally substituted alkyne, such as ethyne; C(O)ORι 1; the group Re; C(O)H; =O; =N-ORι 1; N(H)-OH (or substituted alkyl or aryl derivatives thereof on the nitrogen or the oxime moiety); or N(ORd)-C(O)-Rf. Suitably Rd is hydrogen, a pharmaceutically acceptable cation, aroyl or a Ci-io alkanoyl group.
Suitably Re is a 1,3-dioxyalkylene group of the formula -O-(CH2)s-O-, wherein s is 1 to 3, preferably s is 2 yielding a 1,3-dioxyethylene moiety, or ketal functionality. Suitably Rf is NR21R24; alkyl j.g; halosubstituted alkyl ι_6; hydroxy substituted alkyl 1-6; alkenyl 2-6 ; aryl or heteroaryl optionally substituted by halogen, alkyl 1-6, halosubstituted alkyl 1 -6, hydroxyl, or alkoxy ι_6. Suitably R21 is hydrogen, or alkyl 1 -6. Suitably R24 is hydrogen, alkyl j.g, aryl, benzyl, heteroaryl, alkyl substituted by halogen or hydroxyl, or phenyl substituted by a member selected from the group consisting of halo, cyano, alkyl .5, alkoxy j.g, halosubstituted alkyl ι_6,
S(O)malkyli-6; or R2 and R24 may together with the nitrogen to which they are attached form a ring having 5 to 7 members, which members may be optionally replaced by a heteroatom selected from oxygen, sulfur or nitrogen. The ring may be saturated or contain more than one unsaturated bond. Preferably Rf is NR21R24, and more preferably R21 and R24 are both hydrogen.
When the A or R22 optional substituent is NR13R14 it is recognized that in some instances this can yield the same moiety as a heterocyclic moiety noted above which is also a suitable variable. Preferably R13 and R 14 are independently hydrogen, Cι_4 alkyl, preferably methyl, or benzyl. When the A or R22 optional substituent is a C(Z)ORι 1 group, Rl 1 is suitably hydrogen, Ci-4 alkyl, especially methyl. When the A or R22 optional substituent is a S(O)mRl8 group, Ri8 is preferably aryl, especially phenyl, or a Ci-io alkyl, especially methyl, or ethyl.
When the A or R22 optional substituent is a ORi 1 group, Rl l is preferably hydrogen, aryl, especially phenyl, or Ci-io alkyl, especially methyl or ethyl. When the A or R22 optional substituent is a NHS(O)2Rl8 group, Rl8 is suitably alkyl, especially methyl.
Preferably, R2 is selected from hydrogen, C(H)(A)(R22)» Ci-io alkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylCi-io alkyl, (CRιoR23)nNS(O)2Rl8, (CRlθR23)nS(O)mRl8, arylCi-io alkyl, (CRioR23)n Rl3Rl4, optionally substituted C3-7cycloalkyl, or optionally substituted C3-7cycloalkyl -io alkyl.
When R2 is an optionally substituted heterocyclyl, the ring is preferably a morpholino, pyrrolidinyl, piperazinyl, or a piperidinyl group. When the ring is optionally substituted, the substituents may be directly attached to the free nitrogen, such as in the piperidinyl group or pyrrole ring, or on the ring itself. Preferably the ring is a piperidine or pyrrole, more preferably piperidine. The heterocyclyl ring may be optionally substituted one to four times independently by halogen; C .4 alkyl; aryl, such as phenyl; aryl alkyl, such as benzyl - wherein the aryl or aryl alkyl moieties themselves may be optionally substituted (as in the definition section below); C(O)ORι 1, such as the C(O)Cι_4 alkyl or C(O)OH moieties; C(O)H; C(O)Cι_4 alkyl; hydroxy substituted C1.4 alkyl; Ci-4 alkoxy; S(O)mCi-4 alkyl; or NRιoR20-
Preferably if the ring is a piperidine, the substituents are directly attached on the available nitrogen, i.e. a l-Formyl-4-piperidine, l-benzyl-4-piperidine, l-methyl-4- piperidine, l-ethoxycarbonyl-4-piperidine. If the ring is substituted by an alkyl group and the ring is attached in the 4-position, it is preferably substituted in the 2- or 6- position or both, such as 2,2,6,6-tetramethyl-4-piperidine.
When R2 is an optionally substituted heterocyclyl Ci-io alkyl group, the ring is preferably a morpholino, pyrrolidinyl, piperazinyl or a piperidinyl group. Preferably the alkyl chain is 1 to 4 carbons, more preferably 3 or 4, and most preferably 3, such as in a propyl group. Preferred heterocyclic alkyl groups include but are not limited to, morpholino ethyl, morpholino propyl, pyrrolidinyl propyl, and piperidinyl propyl moieties.
When R2 is an optionally substituted C3-7cycloalkyl, or an optionally substituted C3-7cycloalkyl Ci- o alkyl, the cycloalkyl group is preferably a C3 or C(, ring, most preferably a Cβ ring, which rings may be optionally substituted. The cycloalkyl rings may be optionally substituted one to three times independently by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; OC(O)Rb, Ci-io alkoxy, such as methoxy or ethoxy; S(O)m alkyl, such as methylthio, methylsulfinyl or methylsulfonyl; S(O)maryl; cyano, nitro; NR7R17; N(Rιo)C(O)X and Xi is Ci-4 alkyl, aryl or arylCi-4alkyl; -io alkyl, such as methyl, ethyl, propyl, isopropyl, or t- butyl; optionally substituted alkyl wherein the substituents are halogen, (such as CF3), hydroxy, nitro, cyano, amino, NR7R17, S(O)m alkyl and S(O)m aryl; optionally substituted alkylene, such as ethylene or propylene; optionally substituted alkyne, such as ethyne; C(O)ORι \, such as the free acid or methyl ester derivative; the group Re;
C(O)H; =O; =N-ORn; N(H)-OH (or substituted alkyl or aryl derivatives thereof on the nitrogen or the oxime moiety); N(ORd)-C(O)-Rf; an optionally substituted aryl, such as phenyl; an optionally substituted arylC -4alkyl, such as benzyl or phenethyl; an optionally substituted heterocyclyl or heterocyclic Ci-4alkyl, and further wherein these aryl, arylalkyl, heterocyclic, and heterocyclic alkyl containing moieties are also optionally substituted one to two times by halogen, hydroxy, Ci-io alkoxy, S(O) alkyl, cyano, nitro, amino, mono & di-substituted Ci-6 amino, Ci-io alkyl, or an halosubstituted Ci-io alkyl.
Rb is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylC -4alkyl, heterocyclyl, or heterocyclylCι.4 alkyl; and wherein each of these moieties may be optionally substituted. Rd, Re and Rf are as defined above.
When the R2 cycloalkyl moiety is substituted by NR7R17 group, or NR7R17
Cl-10 alkyl group, and the R7 and R17 are as defined in Formula (I), the substituent is preferably an amino, amino alkyl, or an optionally substituted pyrrolidinyl moiety. In those cases where NR7R17 and NR 3R14 together cyclize to form a 5 to 7 membered ring, it is noted that those rings may be optionally substituted 1 to 3 times as defined in the definition section.
A preferred subgenus of Formula (I) are the compounds of Formula (la) as represented by the general structure:
Figure imgf000026_0001
wherein X = O, NH, or S; V = CH, N; R3 is an optional substituent on the R moiety as defined in Formula (I); R is Ra as defined in Formula (I); Ar is R4 as defined in Formula (I) and R2 is as defined in Formula (I).
A preferred subgenus of Formula (II) are the compounds of Formula (Ila) represented by the general structure :
Figure imgf000027_0001
wherein X = O, NH, or S; V = CH, or N; Rj is Ra as defined in Formula (II); Ar is R4 as defined in Formula (II) and R2 is as defined in Formula (II). A preferred subgenus of Formula (III) are compounds of Formula (Ilia) having the general structure :
Figure imgf000027_0002
wherein X = O, NH, or S; V = CH, or N; Ri is Ra as defined in Formula (III); Ar is R4 as defined in Formula (III) and R2 is as defined in Formula (III).
As used herein, "optionally substituted" unless specifically defined shall mean such groups as halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted Cj-ioalkyl; Cj- o alkoxy, such as methoxy or ethoxy; halosubstituted Ci-io alkoxy; S(O)m alkyl, such as methyl thio, methylsulfinyl or methyl sulfonyl; NR7R17, such as amino or mono or -disubstituted Cj_4 alkyl or wherein the R7R17 can cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally contains an additional heteroatom selected from O/N/S; Ci- o alkyl, C3_7-ycloalkyl, or C3_7cycloalkyl Ci- o alkyl group, such as methyl, ethyl, propyl, isopropyl, t-butyl, etc. or cyclopropyl methyl; halosubstituted Ci-io alkyl, such CF2CF2H, or CF3; an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, wherein these aryl containing moieties may also be substituted one to two times by halogen; hydroxy; hydroxy substituted alkyl; Cι_ιo alkoxy; S(O) alkyl; amino, mono & di-substituted C1.4 alkyl amino, such as in the NR7R 7 group; Cj_4 alkyl, or CF3. Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid.
In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.
The term "halo" or "halogens" is used herein to mean the halogens, chloro, fluoro, bromo and iodo.
The term "Cι _ιoalkyl" or "alkyl" or "alkyl _ιo" is used herein to mean both straight and branched chain radicals of 1 to 10 carbon atoms, unless the chain length is otherwise limited, including, but not limited to, methyl, ethyl, n-propyl, iso- propyl, n-butyl, _ec-butyl, wø-butyl, tert-butyl, n-pentyl and the like.
The term "cycloalkyl" is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl, and the like.
The term "cycloalkenyl" is used herein to mean cyclic radicals, preferably of 5 to 8 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like.
The term "alkenyl" is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-l- propenyl, 1-butenyl, 2-butenyl and the like.
The term "aryl" is used herein to mean phenyl and naphthyl. The term "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or "heteroaryl alkyl") is used herein to mean a 5-10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan, thiophene, quinoline, isoquinoline, quinazolinyl, pyridine, pyrimidine, oxazole, thiazole, thiadiazole, tetrazole, triazole, imidazole, or benzimidazole. The term "heterocyclic" (on its own or in any combination, such as "heterocyclylalkyl") is used herein to mean a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S; such as, but not limited to, pyrrolidine, piperidine, piperazine, morpholine, tetrahydropyran, or imidazolidine.
The term "aralkyl" or "heteroarylalkyl" or "heterocyclicalkyl" is used herein to mean Ci-4 alkyl as defined above attached to an aryl, heteroaryl or heterocyclic moiety as also defined herein unless otherwise indicate.
The term "sulfinyl" is used herein to mean the oxide S (O) of the corresponding sulfide, the term "thio" refers to the sulfide, and the term "sulfonyl" refers to the fully oxidized S (O)2 moiety.
The term "aroyl" is used herein to mean C(O)Ar, wherein Ar is as phenyl, naphthyl, or aryl alkyl derivative such as defined above, such group include but are not limited to benzyl and phenethyl. The term "alkanoyl" is used herein to mean C(O)Ci-io alkyl wherein the alkyl is as defined above.
It is recognized that the compounds of the present invention may exist as stereoisomers, regioisomers, or diastereiomers. These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds are included within the scope of the present invention.
Exemplified compounds of Formula (I), or pharmaceutically acceptable salts thereof, include: l-(Pyrid-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole; 1 -(6-Aminopyrimidin-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole; l-[4-(6,7-Dimethoxyquinazoline)]-3-phenyl-5-(4-fluorophenyl)-l,2,4-triazole;
An exemplified compound of Formula (II), or a pharmaceutically acceptable salt thereof, is 1 -(4-Fluorophenyl)-3-phenyl-5-(2-aminopyrimidin-4-yl)- 1 ,2,4-triazole.
An exemplified compounds of Formula (III), ora pharmaceutically acceptable salt thereof, is:
3-(4-Fluorophenyl)-4-(2-aminopyrimidin-4-yl)-5-phenyl-l,2,4-triazole. The compounds of Formula (I), (II) and (III) may be obtained by applying synthetic procedures, described herein. The synthesis provided for is applicable to producing compounds of Formula (I), (II) or (III) having a variety of different R\, R2, and R4 groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed.
Once the triazole nucleus has been established, further compounds of Formula (I), (II) or (III) may be prepared by applying standard techniques for functional group interconversion, well known in the art. For instance:
C(O)NRi3Ri4 from CO2CH3 by heating with or without catalytic metal cyanide, e.g. NaCN, and HNR13R14 in CH3OH; OC(O)R3 from OH with e.g., ClC(O)R3 in pyridine; NRιo-C(S)NRi3Ri4 from NHR10 with an alkylisothiocyante or thiocyanic acid; NR6C(O)OR6 from NHR6 with the alkyl chloroformate; NRιoC(O)NRi3Ri4 from NHR10 by treatment with an isocyanate, e.g. HN=C=O or RιoN=C=O; NRιo-C(O)R8 from NHR10 by treatment with Cl-C(O)R3 in pyridine; C(=NRio)NRi3Ri4 from C(NRi3Ri4)SR3 with H3NR3+OAc" by heating in alcohol; C(NRi3Ri4)SR3 from C(S)NRi3Ri4 with R6-I in an inert solvent, e.g. acetone; C(S)NR 3Ri4 (where R13 or R14 is not hydrogen) from C(S)NH2 with HNRi3Ri4-C(=NCN)-NRi3Ri4 from C(=NR RI4)-SR3 with NH2CN by heating in anhydrous alcohol, alternatively from C(=NH)-NRi3Ri4 by treatment with BrCN and NaOEt in EtOH;
Figure imgf000030_0001
from NHR10 by treatment with (RsS)2C=NCN; NR10SO2R3 from NHR10 by treatment with CISO2R3 by heating in pyridine; NRιoC(S)R3 from NRιoC(O)R8 by treatment with Lawesson's reagent [2,4-b/_(4-methoxyphenyl)-l,3,2,4-dithiadiphosphetane- 2,4-disulfide]; NR10SO2CF3 from NHRg with triflic anhydride and base wherein R3, R6, RlO. Rl3 and R 14 are as defined in Formula (I) herein.
Precursors of the groups Rj, R2 and R4 can be other R , R2 and R4 groups which can be interconverted by applying standard techniques for functional group interconversion. For example a compound of the formula (I) wherein R2 is halo substituted C „IQ alkyl can be converted to the corresponding C I_IQ alkylN3 derivative by reacting with a suitable azide salt, and thereafter if desired can be reduced to the corresponding C _ o lkylNH2 compound, which in turn can be reacted with Rj S(0)2X wherein X is halo (e.g., chloro) to yield the corresponding C .1 QalkylNHS (0)2R 18 compound. Alternatively a compound of the formula (I), (II) or (III) where R2 is halosubstituted Cι_iQ- lkyl can be reacted with an amine R13R14NH to yield the corresponding Cι_ιo-alkylNR 3R 4 compound, or can be reacted with an alkali metal salt of
Figure imgf000031_0001
compound.
A generally applicable synthesis of Formula (I) triazoles is outlined in Scheme I below which specifically illustrates the case for R2 = aryl, but which may be broadly applicable to all the R2 groups of Formula (I). Condensation of a thioamide with an appropriately activated acyl compound, for example an acid chloride or mixed anhydride, either at low temperature or with heating as required in the presence of an appropriate base and solvent as required affords (1) (1 -scheme- 1). Imide (1) is further reacted with a heterocyclic hydrazine to produce the desired triazole (2) (2-scheme-l) as a final product or as is shown in scheme I as an intermediate. Further conversion of (2) through nucleophilc displacement of a leaving group alpha to the heterocyclic nitrogen, illustrated in Scheme I for chloride, produces (3) (3-scheme-l). Appropriate alpha leaving groups for the displacement are halides and sulfonate esters, such as trifates or mesylates and appropriate nucleophiles are may be either organic or inorganic oxygen, nitrogen or sulfur compounds. For example phenols, alcohols, primary or secondary amines, anilines and either alkyl or aryl sulfides which may be reacted as their metal salts or in the presence of an amine (such as triethylamine or DBU) or inorganic base (such as potassium carbonate) either with or without solvent and heated as required to effect the displacement.
Figure imgf000031_0002
Scheme I
Compounds of the Formula (la) wherein V = CH, R3 = H, X = H can be prepared as described in Example lb herein. Compounds of the Formula (la) wherein V = N, R3 = H, X = H can be prepared as described in Example lb herein except by substituting pyrimidinyl-4-hydrazine (prepared in accordance with the procedures of Crooks et al., Can. J. Chem., 1969, 47, 2061 whose disclosure is incorporated by reference herein in its entirety) for 4-pyridylhydrazine.
Compounds of Formula (la) wherein V = CH, R3 = H, X = O, NH, S can be prepared as described in Example lb herein except by substituting 2-chloropyridyl- 4-hydrazine (prepared in accordance with the procedures of Talik et al, Rocz. Chem., 1955, 29, 1019 whose disclosure is incorporated by reference herein in its entirety) for 4-pyridylhydrazine, and carrying out the nucleophilic displacement of chloride ion as described in US patent No. 5,670,527 example 35, and US patent number 5,658,903, example 27 whose disclosures are incorporated herein by reference in their entirety.
Compounds of the Formula (la) wherein V = N, R3 = H, X = O, NH, S can be prepared as described in Example lb herein by substituting 2-(methylthio)pyrimidine-4- hydrazine (prepared by heating 4-chloro-2-(methylthio)pyrimidine with hydrazine) for (4-pyridyl)hydrazine, and carrying out the oxidation/displacement protocol as described in US patent number 5,716,955 (Scheme II) whose disclosure is incorporated herein by reference in its entirety. The conditions for the displacement of alkyl sulfide or the sulfoxide or sulfone oxidation states thereof and the potential nucleophiles are the same as those described in Scheme I and are represented in Scheme II for RiX as defined in Formula (I).
Compounds of the Formula (la) wherein V = CH, Rl = H, R3 = H, X = O, NH, S and V = N, Rl = H, R3 = H, X = O, NH, S can be prepared such as described in US
Patent No. 5,716,955 whose disclosure is incorporated herein by reference in its entirety,
Figure imgf000032_0001
Scheme II A generally applicable synthesis of Formula (II) triazoles is outlined in Scheme III below which specifically illustrates the case for R^ = substituted pyrimidine, but which may be broadly applicable to all the R groups of Formula (II).
Figure imgf000033_0001
Figure imgf000033_0002
Scheme III
Compounds of Formula (Ila) wherein V = N, X = O, NH, or S can be prepared as shown in the scheme above. 2-(Methylthio)pyrimidine-4-carboxylic acid (prepared according to the method of Kim et al, J. Med. Chem., 1986, 29, 1374 whose disclosure is incorporated herein by reference in its entirety) is converted to the acyl chloride
(refluxing thionyl chloride). Following the procedure of Lin et al (J. Heterocyclic
Chem., 1983, 20, 1693 whose disclosure is incorporated herein by reference in its entirety) triazoles can be prepared by condensing the acyl chloride with thioamides to form the corresponding monothioimides. The monothioimides are then condensed with arylhydrazines to afford the 1,2,4-triazole nuclei. Displacement of the methylthio group (Ri-X not H) with nucleophiles (X=O, NH, S) can be effected by oxidation to the methylsulfinyl derivative with 3 -chloroperoxy benzoic acid or oxone, followed by displacement with nucleophiles with or without the addition of bases such as sodium hydride, organolithiums or trialkylamines. In the case of amines (X=N), aluminum amide derivatives can be used to effect the displacements.
Compounds of Formula (Ila) wherein V=C, X= O, NH, S can be prepared as described above except substituting 2-chloropyridine-4-carboxylic acid for 2- (methylthio)pyrimidine-4-carboxylic, and carrying out the nucleophilic displacements of chloride ion according to the protocol described in US patent #
5,670,527 example 35, and US patent number 5,658,903; example 27 for l-(4- piperidinyl)-4-(4-fluorophenyl)-5-(2-anilino-4-pyridinyl)imidazole whose disclosures are incorporated herein by reference in their entirety.
Compounds of the Formula (Ila) wherein V = CH, Rl = H, X = O, NH, S and V
= N, Rl = H, X = O, NH, S can be prepared as described in US Patent No. 5,716,955 whose disclosure is incorporated by reference herein in its entirety.
A generally applicable synthesis of Formula (III) triazoles is outlined in Scheme IV below which specifically illustrates the case for R\ = substituted pyrimidine, but which may be broadly applicable to all the R^ groups of Formula (III).
Figure imgf000034_0001
Scheme IV
Compounds of Formula (III) wherein V = N, and X = O, NH, or S can be prepared as shown in the above scheme. Condensation of an activated ester with hydrazine yields the acylhydrazide, which upon treatment with a second activated ester, affords the 1,2-diacylhydrazide. Condensation with 4-amino-2- (methylthio)pyrimidine (prepared according to Brown et al, J. Chem. Soc, 1962, 3172 whose disclosure is incorporated herein by reference in its entirety) gives the triazole nucleus. Substitution of the methylthio group via an oxidation/displacement protocol as described for compounds of Formula (III) will allow one to access the 2- substituted pyrimidines. Compounds of the Formula (Ilia) wherein V = CH, and X = O, N, or S can be prepared as described above except substituting 4-amino-2-chloropyridine for 4- amino-2-(methylthio)pyrimidine, and carrying out the nucleophilic displacements of chloride ion according to the protocol described in US patent number 5,670,527 example 35, and US patent number 5,658,903; example 27 for l-(4-piperidinyl)-4- (4-fluorophenyl)-5-(2-anilino-4-pyridinyl)imidazole whose disclosures are incorporated herein by reference in their entirety.
Compounds of the Formula (Ilia) wherein V = CH, Rl = H, X = O, NH, S and V = N, Rl = H, X = O, NH, S can be prepared as described in US patent No. 5,716,955 whose disclosure is incorporated herein by reference in its entirety.
Suitable protecting groups for use with hydroxyl groups and nitrogen groups are well known in the art and described in many references, for instance, Protecting Groups in Organic Synthesis, Greene T W, Wiley-Interscience, New York, 1981. Suitable examples of hydroxyl protecting groups include silyl ethers, such as t- butyldimethyl or t-butyldiphenyl, and alkyl ethers, such as methyl connected by an alkyl chain of variable link, (CRlθR2θ)n-
Pharmaceutically acid addition salts of compounds of Formula (I) may be obtained in known manner, for example by treatment thereof with an appropriate amount of acid in the presence of a suitable solvent.
METHODS OF TREATMENT
The compounds of Formula (I) or a pharmaceutically acceptable salt thereof can be used in the manufacture of a medicament for the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated cytokine production by such mammal's cell, such as but not limited to monocytes and/or macrophages.
Compounds of Formula (I) are capable of inhibiting proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF and are therefore of use in therapy. IL- 1, EL-6, IL-8 and TNF affect a wide variety of cells and tissues and these cytokines, as well as other leukocyte-derived cytokines, are important and critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these pro-inflammatory cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
Accordingly, the present invention provides a method of treating a cytokine- mediated disease which comprises administering an effective cytokine-interfering amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Compounds of Formula (I) are capable of inhibiting inducible proinflammatory proteins, such as COX-2, also referred to by many other names such as prostaglandin endoperoxide synthase-2 (PGHS-2) and are therefore of use in therapy. These proinflammatory lipid mediators of the cyclooxygenase (CO) pathway are produced by the inducible COX-2 enzyme. Regulation, therefore of COX-2 which is responsible for the these products derived from arachidonic acid, such as prostaglandins affect a wide variety of cells and tissues are important and critical inflammatory mediators of a wide variety of disease states and conditions. Expression of COX-1 is not effected by compounds of Formula (I). This selective inhibition of COX-2 may alleviate or spare ulcerogenic liability associated with inhibition of COX-1 thereby inhibiting prostoglandins essential for cytoprotective effects. Thus inhibition of these pro-inflammatory mediators is of benefit in controlling, reducing and alleviating many of these disease states. Most notably these inflammatory mediators, in particular prostaglandins, have been implicated in pain, such as in the sensitization of pain receptors, or edema. This aspect of pain management therefore includes treatment of neuromuscular pain, headache, cancer pain, and arthritis pain. Compounds of Formula (I) or a pharmaceutically acceptable salt thereof, are of use in the prophylaxis or therapy in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme. Accordingly, the present invention provides a method of inhibiting the synthesis of COX-2 which comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. The present invention also provides for a method of prophylaxis treatment in a human, or other mammal, by inhibition of the synthesis of the COX-2 enzyme. In particular, compounds of Formula (I) or a pharmaceutically acceptable salt thereof are of use in the prophylaxis or therapy of any disease state in a human, or other mammal, which is exacerbated by or caused by excessive or unregulated IL-1, IL-6, IL-8 or TNF production by such mammal's cell, such as, but not limited to, monocytes and/or macrophages. Accordingly, in another aspect, this invention relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
There are many disease states in which excessive or unregulated IL-1 production is implicated in exacerbating and/or causing the disease. These include rheumatoid arthritis, osteoarthritis, stroke, endotoxemia and/or toxic shock syndrome, other acute or chronic inflammatory disease states such as the inflammatory reaction induced by endotoxin or inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, multiple sclerosis, cachexia, bone resorption, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis. Recent evidence also links IL-1 activity to diabetes, pancreatic β cells disease, and Alzheimer's disease.
In a further aspect, this invention relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Excessive or unregulated TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, stroke, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, such as osteoporosis, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis and pyresis.
Compounds of Formula (I) are also useful in the treatment of viral infections, where such viruses are sensitive to upregulation by TNF or will elicit TNF production in vivo. The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibiting-compounds of Formula (1). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, Cytomegalovirus (CMV), Influenza, adenovirus and the Herpes group of viruses, such as but not limited to, Heφes Zoster and Heφes Simplex. Accordingly, in a further aspect, this invention relates to a method of treating a mammal afflicted with a human immunodeficiency virus (HIV) which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. It is also recognized that both IL-6 and IL-8 are produced during rhinovirus
(HRV) infections and contribute to the pathogenesis of common cold and exacerbation of asthma associated with HRV infection (Turner et al. (1998), Clin. Infec. Dis., Vol 26, p 840; Teren et al. (1997), Am J Respir Crit Care Med vol 155, pl362; Grunberg et al. (1997), Am J Respir Crit Care Med 156:609 and Zhu et al, J Clin Invest (1996), 97:421). It has also been demonstrated in vitro that infection of pulmonary epithelial cells with HRV results in production of IL-6 and IL-8 (Subauste et al., J. Clin. Invest. 1995, 96:549.) Epithelial cells represent the primary site of infection of HRV. Therefore another aspect of the present invention is a method of treatment to reduce inflammation associated with a rhinovirus infection, not necessarily a direct effect on virus itself. Compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than in humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.
The compounds of Formula (I) may also be used topically in the treatment or prophylaxis of topical disease states mediated by or exacerbated by excessive cytokine production, such as by IL-1 or TNF respectively, such as inflamed joints, eczema, psoriasis and other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation. Compounds of Formula (I) have also been shown to inhibit the production of
IL-8 (Interleukin-8, NAP). Accordingly, in a further aspect, this invention relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and/or causing the disease. These diseases are characterized by massive neutrophil infiltration such as, psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis. All of these diseases are associated with increased IL-8 production which is responsible for the chemotaxis of neutrophils into the inflammatory site. In contrast to other inflammatory cytokines (IL-1, TNF, and IL-6), IL-8 has the unique property of promoting neutrophil chemotaxis and activation. Therefore, the inhibition of IL-8 production would lead to a direct reduction in the neutrophil infiltration. The compounds of Formula (I) are administered in an amount sufficient to inhibit cytokine, in particular IL-1, IL-6, IL-8 or TNF, production such that it is regulated down to normal levels, or in some case to subnormal levels, so as to ameliorate or prevent the disease state. Abnormal levels of IL-1, IL-6, IL-8 or TNF, for instance in the context of the present invention, constitute: (i) levels of free (not cell bound) IL-1, IL-6, IL-8 or TNF greater than or equal to 1 picogram per ml; (ii) any cell associated IL-1, IL-6, IL-8 or TNF; or (iii) the presence of IL-1, IL-6, IL-8 or TNF mRNA above basal levels in cells or tissues in which IL-1, IL-6, IL-8 or TNF, respectively, is produced.
The discovery that the compounds of Formula (I) are inhibitors of cytokines, specifically IL-1, IL-6, IL-8 and TNF is based upon the effects of the compounds of Formulas (I) on the production of the E -l, IL-8 and TNF in in vitro assays which are described herein.
As used herein, the term "inhibiting the production of IL-1 (IL-6, IL-8 or TNF)" refers to: a) a decrease of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels by inhibition of the in vivo release of the cytokine by all cells, including but not limited to monocytes or macrophages; b) a down regulation, at the genomic level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels; c) a down regulation, by inhibition of the direct synthesis of the cytokine (IL- 1 , IL-6, IL-8 or TNF) as a postranslational event; or d) a down regulation, at the translational level, of excessive in vivo levels of the cytokine (IL-1, IL-6, IL-8 or TNF) in a human to normal or sub-normal levels.
As used herein, the term "TNF mediated disease or disease state" refers to any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another monokine to be released, such as but not limited to IL-1, IL-6 or IL-8. A disease state in which, for instance, IL-1 is a major component, and whose production or action, is exacerbated or secreted in response to TNF, would therefore be considered a disease stated mediated by TNF.
As used herein, the term "cytokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines, such as natural killer cells, fϊbroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes and B -lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-a) and Tumor Necrosis Factor beta (TNF-β). As used herein, the term "cytokine interfering" or "cytokine suppressive amount" refers to an effective amount of a compound of Formula (I) which will cause a decrease in the in vivo levels of the cytokine to normal or sub-normal levels, when given to a patient for the prophylaxis or treatment of a disease state which is exacerbated by, or caused by, excessive or unregulated cytokine production. As used herein, the cytokine referred to in the phrase "inhibition of a cytokine, for use in the treatment of a HIV-infected human" is a cytokine which is implicated in (a) the initiation and/or maintenance of T cell activation and/or activated T cell- mediated HIV gene expression and/or replication and/or (b) any cytokine-mediated disease associated problem such as cachexia or muscle degeneration. As TNF-β (also known as lymphotoxin) has close structural homology with
TNF-a (also known as cachectin) and since each induces similar biologic responses and binds to the same cellular receptor, both TNF-a and TNF-β are inhibited by the compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise. A new member of the MAP kinase family, alternatively termed CSBP, p38, or RK, has been identified independently by several laboratories. Activation of this novel protein kinase via dual phosphorylation has been observed in different cell systems upon stimulation by a wide spectrum of stimuli, such as physicochemical stress and treatment with lipopolysaccharide or proinflammatory cytokines such as interleukin-1 and tumor necrosis factor. The cytokine biosynthesis inhibitors, of the present invention, compounds of Formula (I) have been determined to be potent and selective inhibitors of CSBP/p38/RK kinase activity. These inhibitors are of aid in determining the signaling pathways involvement in inflammatory responses. In particular, for the first time a definitive signal transduction pathway can be prescribed to the action of lipopolysaccharide in cytokine production in macrophages. In addition to those diseases already noted, treatment of stroke, neurotrauma, cardiac and renal reperfusion injury, congestive heart failure, chronic renal failure, angiogenesis & related processes, such as cancer, thrombosis, glomerulonephritis, diabetes and pancreatic b cells, multiple sclerosis, muscle degeneration , eczema, psoriasis, sunburn, and conjunctivitis are also included. The CSBP inhibitors were subsequently tested in a number of animal models for anti-inflammatory activity. Model systems were chosen that were relatively insensitive to cyclooxygenase inhibitors in order to reveal the unique activities of cytokine suppressive agents. The inhibitors exhibited significant activity in many such in vivo studies. Most notable are its effectiveness in the collagen-induced arthritis model and inhibition of TNF production in the endotoxic shock model. In the latter study, the reduction in plasma level of TNF correlated with survival and protection from endotoxic shock related mortality. Also of great importance are the compounds effectiveness in inhibiting bone resoφtion in a rat fetal long bone organ culture system. Griswold et al., (1988) Arthritis Rheum. 31: 1406-1412; Badger, et al., (1989) Circ. Shock 27, 51-61; Votta et al., (1994)w vitro. Bone 15, 533-538; Lee et al., (1993). B Ann. N Y. Acad. Sci. 696, 149-170.
Chronic diseases which have an inappropriate angiogenic component are various ocular neovasularizations, such as diabetic retinopathy and macular degeneration. Other chronic diseases which have an excessive or increased proliferation of vasculature are tumor growth and metastasis, atherosclerosis, and certain arthritic conditions. Therefore CSBP kinase inhibitors will be of utility in the blocking of the angiogenic component of these disease states.
The term "excessive or increased proliferation of vasculature inappropriate angiogenesis" as used herein includes, but is not limited to, diseases which are characterized by hemangiomas and ocular diseases.
The term "inappropriate angiogenesis" as used herein includes, but is not limited to, diseases which are characterized by vesicle proliferation with accompanying tissue proliferation, such as occurs in cancer, metastasis, arthritis and atherosclerosis.
Accordingly, the present invention provides a method of treating a CSBP kinase mediated disease in a mammal in need thereof, preferably a human, which comprises administering to said mammal, an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent. Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incoφorating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed. Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg. When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
Compounds of Formula (I) may be administered topically, that is by non- systemic administration. This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration. Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1% to 1% w/w of the formulation.
Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops. Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base. The base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glyeol or a macrogel. The formulation may incoφorate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof. Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100°C. for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique. Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%). Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glyeol.
Compounds of Formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques. Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques.
For all methods of use disclosed herein for the compounds of Formula (I), the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg kg of total body weight, preferably from about 0.2 to 30 mg/kg, more preferably from about 0.5 mg to 15mg. The daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg. The daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests. The novel compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of CSBP/p38 or cytokine inhibition or production. In particular, CSBP/p38 mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section, but in particular viral infections. Examples of such viruses include, but are not limited to, lentivirus infections such as, equine infectious anaemia virus, caprine arthritis virus, visna virus, or maedi virus or retrovirus infections, such as but not limited to feline immunodeficiency virus (FIV), bovine immunodeficiency virus, or canine immunodeficiency virus or other retroviral infections.
The invention will now be described by reference to the following biological examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.
BIOLOGICAL EXAMPLES
The cytokine-inhibiting effects of compounds of the present invention may be determined by the following in vitro assays:
Assays for Interleukin - 1 (D -1), Interleukin -8 (IL-8 ), and Tumour Necrosis Factor (TNF) are well known in the art, and may be found in a number of publications, and patents. Representative suitable assays for use herein are described in Adams et al., US 5,593,992, whose disclosure is incoφorated by reference in its entirety.
Interleukin - 1 (IL-1)
Human peripheral blood monocytes are isolated and purified from either fresh blood preparations from volunteer donors, or from blood bank buffy coats, according to the procedure of Colotta et al, J Immunol, 132, 936 (1984). These monocytes (1x10^) are plated in 24- well plates at a concentration of 1-2 million/ml per well. The cells are allowed to adhere for 2 hours, after which time non-adherent cells are removed by gentle washing. Test compounds are then added to the cells for lh before the addition of lipopolysaccharide (50 ng/ml), and the cultures are incubated at 37°C for an additional 24h. At the end of this period, culture supernatants are removed and clarified of cells and all debris. Culture supernatants are then immediately assayed for IL- 1 biological activity, either by the method of Simon et al, J. Immunol. Methods, 84, 85, (1985) (based on ability of IL-1 to stimulate a Interleukin 2 producing cell line (EL-4) to secrete IL-2, in concert with A23187 ionophore) or the method of Lee et al., J. ImmunoTherapy, 6 (1), 1-12 (1990) (ELISA assay). Compounds of Formula (I), exemplified by Example 1, were found to be active in this assay having an IC50 of < 7uM.
In vivo TNF assay:
(1) Griswold et al., Drugs Under Exp. and Clinical Res.,XIX (6). 243-248 (1993); or
(2) Boehm, et al., Journal Of Medicinal Chemistry 39, 3929-3937 (1996) whose disclosures are incoφorated by reference herein in their entirety. LPS-induced TNFα Production in Mice and Rats
In order to evaluate in vivo inhibition of LPS-induced TNFα production in rodents, both mice and rats are injected with LPS. Mouse Method
Male Balb/c mice from Charles River Laboratories are pretreated (30 minutes) with compound or vehicle. After the 30 min. pretreat time, the mice are given LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO) 25 ug/mouse in 25 ul phosphate buffered saline (pH 7.0) intraperitoneally. Two hours later the mice are killed by CO2 inhalation and blood samples are collected by exsanguination into heparinized blood collection tubes and stored on ice. The blood samples are centrifuged and the plasma collected and stored at -20°C until assayed for TNFα by ELISA.
Rat Method
Male Lewis rats from Charles River Laboratories are pretreated at various times with compound or vehicle. After a determined pretreat time, the rats are given
LPS (lipopolysaccharide from Esherichia coli Serotype 055-85, Sigma Chemical Co., St Louis, MO) 3.0 mg/kg intraperitoneally. The rats are killed by CO2 inhalation and heparinized whole blood is collected from each rat by cardiac puncture 90 minutes after the LPS injection. The blood samples are centrifuged and the plasma collected for analysis by ELISA for TNFα levels.
ELISA Method TNFα levels were measured using a sandwich ELISA, as described in Olivera et al., Circ. Shock, 37, 301-306, (1992), whose disclosure is incoφorated by reference in its entirety herein, using a hamster monoclonal antimurine TNFα (Genzyme, Boston, MA) as the capture antibody and a polyclonal rabbit antimurine TNFa (Genzyme) as the second antibody. For detection, a peroxidase-conjugated goat antirabbit antibody (Pierce, Rockford, IL) was added, followed by a substrate for peroxidase (1 mg/ml orthophenylenediamine with 1% urea peroxide). TNFα levels in the plasma samples from each animal were calculated from a standard curve generated with recombinant murine TNFα (Genzyme).
LPS-Stimulated Cytokine Production in Human Whole Blood
Assay: Test compound concentrations were prepared at 10 X concentrations and LPS prepared at 1 ug/ml (final cone, of 50 ng/ml LPS) and added in 50 uL volumes to 1.5 mL eppendorf tubes. Heparinized human whole blood was obtained from healthy volunteers and was dispensed into eppendorf tubes containing compounds and LPS in 0.4 mL volumes and the tubes incubated at 37 C. Following a 4 hour incubation, the tubes were centrifuged at 5000 φm for 5 minutes in a TOMY microfuge, plasma was withdrawn and frozen at -80 C.
Cytokine measurement: IL-I and or TNF were quantified using a standardized ELISA technology. An in-house ELISA kit was used to detect human IL-1 and TNF. Concentrations of IL-1 or TNF were determined from standard curves of the appropriate cytokine and IC50 values for test compound (concentration that inhibited 50% of LPS-stimulated cytokine production) were calculated by linear regression analysis.
CSBP/p38 Kinase Assay: This assay measures the CSBP/p38-catalyzed transfer of 32p from [a-
32p]ATP to threonine residue in an epidermal growth factor receptor (EGFR)-derived peptide (T669) with the following sequence: KRELVEPL7PSGEAPNQALLR (residues 661-681). (See Gallagher et al., "Regulation of Stress Induced Cytokine Production by Pyridinyl Imidazoles: Inhibition of CSBP Kinase", BioOrganic & Medicinal Chemistry, 1997, 5, 49-64).
Reactions were carried in round bottom 96 well plate (from Corning) in a 30 ml volume. Reactions contained (in final concentration): 25 mM Hepes, pH 7.5; 8 mM MgCl2; 0.17 mM ATP (the KmrATP] of P38 (see Lee et al., Nature 300, n72 pg. 639-746 (Dec. 1994)); 2.5 uCi of [g-32P]ATP; 0.2 mM sodium orthovanadate; 1 mM DTT; 0.1% BSA; 10% glycerol; 0.67 mM T669 peptide; and 2-4 nM of yeast- expressed, activated and purified p38. Reactions were initiated by the addition of [gamma-32P]Mg/ATP, and incubated for 25 min. at 37 °C. Inhibitors (dissolved in DMSO) were incubated with the reaction mixture on ice for 30 minutes prior to adding the 32P-ATP. Final DMSO concentration was 0.16%. Reactions were terminated by adding 10 ul of 0.3 M phosphoric acid, and phosphorylated peptide was isolated from the reactions by capturing it on p81 phosphocellulose filters. Filters were washed with 75 mM phosphoric acids, and incoφorated 32P was quantified using beta scintillation counter. Under these conditions, the specific activity of p38 was 400-450 pmol/pmol enzyme, and the activity was linear for up to 2 hr of incubation. The kinase activity values were obtained after subtracting values generated in the absence of substrate which were 10-15% of total values. Representative final compounds of Formula (I), Example 2 demonstrated positive inhibitory activity of an IC50 of < 50uM in this binding assay or a similar assay. Example 3 was found not to be active in this binding assay at concentrations of lOOuM.
Prostoglandin endoperoxide synthase-2 (PGHS-2) assay:
This assay describes a method for determining the inhibitory effects of compounds of Formula (I) on human PGHS-2 protein expression in LPS stimulated human monocytes. A suitable assay for PGHS-2 protein expression may be found in a number of publications, including US Patent 5,593,992 whose disclosure is incoφorated herein by reference.
TNF-a in Traumatic Brain Injury Assay
This assay provides for examination of the expression of tumor necrosis factor mRNA in specific brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats. Since TNF- a is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF- a plays an important role in both the acute and regenerative response to CNS trauma. A suitable assay may be found in WO 97/35856 whose disclosure is incoφorated herein by reference.
CNS Injury model for IL-b mRNA
This assay characterizes the regional expression of interleukin- lβ (IL-lβ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats. Results from these assays indicate that following TBI, the temporal expression of IL-lβ mRNA is regionally stimulated in specific brain regions. These regional changes in cytokines, such as IL-1 β play a role in the post- traumatic pathologic or regenerative sequelae of brain injury. A suitable assay may be found in WO 97/35856 whose disclosure is incoφorated herein by reference. Angiogenesis Assay:
Described in WO 97/32583, whose disclosure is incoφorated herein by reference, is an assay for determination of inflammatory angiogenesis which may be used to show that cytokine inhibition will stop the tissue destruction of excessive or inappropriate proliferation of blood vessels.
SYNTHETIC EXAMPLES
The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention. All temperatures are given in degrees centigrade, all solvents are highest available purity and all reactions run under anhydrous conditions in an argon atmosphere unless otherwise indicated.
In the Examples, all temperatures are in degrees Centigrade (°C). Mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment or on a micromass platform electrospray ionization mass spectrometer in the positive ion mode using 95:5 CH3CN/CH3OH with 1% formic acid as the carrier solvent, unless otherwise indicated. 1H-NMR (hereinafter "NMR") spectra were recorded at 250 MHz using a Bruker AM 250 or Am 400 spectrometer. Multiplicities indicated are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet and br indicates a broad signal. Sat. indicates a saturated solution, eq indicates the proportion of a molar equivalent of reagent relative to the principal reactant.
Flash chromatography is run over Merck Silica gel 60 (230 - 400 mesh).
Example 1 1 -(Pyrid-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole
Figure imgf000049_0001
a) N-(4-Fluorobenzoyl)thiobenzamide
To a solution of 4-fluorobenzoylchloride (1.3g, 8.5mmol) in acetone (7.0ml) was added a solution of thiobenzamide (1.16g, 8.5mmol) and pyridine (0.66g, 8.5mmol) in acetone (7.0ml). The mixture was refluxed for 6h. and cooled to room temperature. The reaction mixture was poured into water/ice and extracted with chloroform. Flash chromatography on silica gel afforded 0.5g of the title compound as a red solid.
b) 1 -(Pyrid-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole To a solution of N-(4-fluorobenzoyl)thiobenzamide (0.5g, 1.9mmol), (4- pyridyl)hydrazine hydrochloride (0.336g, 2.3mmol) and sodium acetate (0.19g, 2.3mmol) in acetic acid/ dioxane (6ml l:l) was stirred at 90°C for 24h. The reaction mixture was cooled and evaporated in vacuo. The residue was purified by flash chromatography on silica gel. Elution with ethylacetate/hexane (1:4) and subsequent crystallization afforded the triazole as a white solid, m.p. 134-135°C.
Example 2 l-(6-Aminopyrimidin-4-yl)-3-phenyl-5-(4-fluorophenyl)-1.2,4-triazole
Figure imgf000050_0001
a) (4-Chloropyrimidin-6-yl)hydrazine hydrochloride
Hydrazine hydrate (0.89 ml, 0.92 g, 1.8 mmol) was added to 4,6-dichloropyrimidine (2.5 g, 1.7 mmol) in ethanol (25 ml) at 0 °C. After stirring the reaction mixture at this temperature for 0.5 h, the precipitate which formed was collected and washed with ethanol to afford the title compound as a white solid; yield 1.5 g. b) l-(4-Chloropyrimidin-6-yl)-3-phenyl-5-(4-fluorophenyl)-l,2,4-triazole Following the procedure of Example lb except substituting (4-chloropyrimidin-6- yl)hydrazine hydrochloride for f4-pyridyl)hydrazine afforded the title compound as a white solid in 34 % yield: *H NMR (CDCI3) δ 8.69 (s, IH), 8.26 (dd, 2H), 8.07 (s,
IH), 7.71 (dd, 2H), 7.52 (m, 3H), 7.18 (t, 2H). c) 1 -(6-Aminopyrimidin-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole
A mixture of l-(4-chloropyrimidin-6-yl)-3-phenyl-5-(4-fluorophenyl)-l,2,4-triazine (0.080 g, 0.23 mmol) and concentrated NH4OH was heated to 120°C for 18 h in a sealed reaction vessel. After cooling the reaction to ambient temperature, the precipitate which had formed was collected and washed with water, air-dried and dried in vacuo at 40°C to afford the title compound as a white solid; yield 0.030g (39 %): ES MS m/z =333 (MH+).
Example 3 l-r4-(6,7-Dimethoxyquinazoline)1-3-phenyl-5-(4-fluorophenyl)-1.2,4-triazole
Figure imgf000051_0001
a) 6,7-Dimethoxyquinazoline-l- hydrazine hydrochloride Chloro-6,7-dimethoxyquinazoline (6g, 26.79 mmol) and hydrazine monohydrate (2.7g, 54.79 mmol) in ethanol were stirred together at 75°C for 3 h. Most of ethanol was evaporated in high vacuo. The resulting solid was washed with hexane (3X). Recrystallization from EtOAc/hexane (1:2) afforded the title compound (5.1g). ES MS m/z 237 (MH+). b) 1 -[4-(6,7-Dimethoxyquinazoline)1-3-phenyl-5-(4-fluorophenyl)- 1.2,4- triazole
The title compound was prepared as described in Example lb except substituting 6,7-dimethoxyquinazoline-l -hydrazine hydrochloride for (4-pyridyl)hydrazine. m.p. 228-230°C. All publications, including but not limited to patents and patent applications, cited in this specification are herein incoφorated by reference as if each individual publication were specifically and individually indicated to be incoφorated by reference herein as though fully set forth.
The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent. Therefore, the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

Claims

00/10563What is Claimed is:
1. A compound of the formula :
Figure imgf000053_0001
wherein Ri is a pyrid-4-yl, or a pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, Ci-4 alkyl, halogen, hydroxyl, Ci-4 alkoxy, C -4 alkylthio, Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(Rjo)C(O)Rb or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR 5; is X╬╣-Ra;
Xj is sulfur, oxygen, or NH;
Ra is Cj-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylC╬╣_6alkyl, wherein each of these moieties may be optionally substituted;
R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR╬│Ri7, C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR 12, halo-substituted-Ci-4 alkyl, Ci-4 alkyl, ZC(Z)Ri2, NR╬╣oC(Z)Ri6, or (CR╬╣oR2╬╕)vNRl╬╕R20 and which, for other positions of substitution, is halogen, cyano, C(Z)NRi3Ri4, C(Z)OR3, (CRioR20)m"COR3, S(O)mR3, OR3, halo-substituted-Ci-4 alkyl, C1-4 alkyl, (CR╬╣oR2╬╕)m"NRl╬╕C(Z)R3, NR╬╣0S(O)m'R8, NR╬╣0S(O)m'NR7Rl7, ZC(Z)R3 or (CRioR20)m"NRl3Rl4;
Z is oxygen or sulfur; n is 0, or an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2;
R2 is hydrogen, C(H)(A)(R22), (CRl╬╕R23)n ORo, (CR╬╣oR23)nORi 1, C.-ioalkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylCi_ o alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi- oalkyl, heterocyclyl, heterocyclylCi-io alkyl, (CR╬╣oR23)nS(O)mRi8, (CR╬╣0R23)nNHS(O)2Rl8, (CR╬╣0R23)nNRl3Rl4, (CR╬╣oR23)nNO2, (CR╬╣0R23)nCN, (CR╬╣oR23)nS(O)m'NRi3Rl4, (CRioR230)nC(Z)Ri 1, (CR╬╣0R23)nOC(Z)R╬╣ 1, (CR╬╣0R23)nC(Z)OR╬╣ 1,
(CRιoR23)nC(Z)NRι3Rl4, (CRlθR23)nC(Z)NRι ιOR9) (CRioR23)nNRioC(Z)Rπ, (CRιoR23)nNRlθC(Z)NRi3Rl4, (CRlθR23)nN(OR6)C(Z)NRι3Rl4, (CRι0R23)nN(OR6)C(Z)Rι i, (CRioR23)nC(=NOR6)Rl 1, (CRιoR23)nNRioC(=NRi9)NRι3Rl4, (CRιoR23)nOC(Z)NRi3Rl4, (CRlθR23)nNRiθC(Z)NRι3Ri4,
(CRioR23)nNRl╬╕C(Z)OR╬╣o, 5-(Ri8)-l,2,4-oxadizaol-3-yl or 4-(Ri2)-5- (Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; wherein the cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl groups may be optionally substituted; A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted C 1-10 alkyl; R22 is an optionally substituted Cj_ o alkyl; Rb is hydrogen, -6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; and wherein each of these moieties may be optionally substituted;
R3 is heterocyclyl, heterocyclylCi-io alkyl or R╬┤;
R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R 7, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
R6 is hydrogen, a pharmaceutically acceptable cation, C╬╝io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl; R7 and R17 is each independently selected from hydrogen or C -4 alkyl or R7 and Rl7 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15;
R is Ci-io alkyl, halo-substituted -io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CRi0R20)nORl l, (CR╬╣0R2╬╕)nS(O)mRi8, (CRioR2╬╕)nNHS(O)2Rl8, (CRioR20)nNRl3Rl4; and wherein the aryl, arylalkyl, heteroaryl, or heteroaryl alkyl moieties may be optionally substituted; R9 is hydrogen, C(Z)R╬╣ 1 or optionally substituted Ci-io alkyl, S(O)2Rl8> optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl; RlO and R20 are each independently selected from hydrogen or C 1.4 alkyl; Rl 1 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylCi-io alkyl, wherein all of these moieties may be optionally substituted; Rl2 is hydrogen or Ri6; Rl3 and R14 is each independently selected from hydrogen or optionally substituted
Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-C╬╣.4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of
5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9 ; Rl 5 is Rio or C(Z)-Ci-4 alkyl;
Rl6 is Ci-4 alkyl, halo-substituted-Ci-4 alkyl, or C3..7 cycloalkyl; Ri8 is Ci- o alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroaryl i-ioalkyl; Rl9 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl or aryl; R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or a heterocyclylCi-4 alkyl moiety, wherein all of these moieties may be optionally substituted; or a pharmaceutically acceptable salt thereof.
2. The compound according to Claim 1 wherein Ri is an optionally substituted pyrid-4-yl.
3. The compound according to Claim 1 wherein Ri is an optionally substituted pyrimidin-4-yl.
4. The compound according to Claim 1 wherein the R\ optional substituent is Y.
5. The compound according to Claim 4 wherein the Ra moiety is alkyl, aryl, or arylalkyl.
6. The compound according to Claim 1 wherein R4 is an optionally substituted phenyl.
7. The compound according to Claim 6 wherein the phenyl is substituted one or more times independently by halogen, SR5, S(O)R5, OR 12, halo-substituted-Ci-4 alkyl, or C 1-4 alkyl.
8. The compound according to Claim 1 wherein R2 is hydrogen, C(H)(A)(R22), aryl, arylalkyl, heterocyclic, heterocyclicalkyl, heteroaryl and heterocyclic alkyl; and wherein the aryl, heteroaryl or heterocyclic containing moieties may be optionally substituted.
9. The compound according to Claim 8 wherein R2 is an optionally substituted aryl.
10. The compound according to Claim 1 which is:
1 -(Pyrid-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole 1 -(6-Aminopyrimidin-4-yl)-3-phenyl-5-(4-fluorophenyl)- 1 ,2,4-triazole l-[4-(6,7-Dimethoxyquinazoline)]-3-phenyl-5-(4-fluorophenyl)-l,2,4-triazole; or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising an effective amount of a compound according to any of Claims 1 to 10 and a pharmaceutically acceptable carrier or diluent.
12. A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound of Formula (I) according to any one of Claims 1 to 10.
13. The method according to Claim 13 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resoφtion disease, osteoporosis, restenosis, CNS injury, cardiac and renal reperfusion injury, chronic renal failure, congestive heart failure, angiogenic diseases, thrombosis, glomerularnephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermititis, psoriasis, sunburn, conjunctivitis, or rhinovirus infection.
14. A compound of the formula :
Figure imgf000057_0001
wherein
Rl is a pyrid-4-yl or a pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, Ci-4 alkyl, halogen, hydroxyl, C}-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylsulfinyl, CH2OR 2, amino, mono and di- Ci-6 alkyl substituted amino, N(R╬╣o)C(O)RD or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR15;
Y is X╬╣-Ra;
X is sulfur, oxygen, or NH; Ra is Ci-6alkyl, aryl, arylCj-όalkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylCi-6alkyl, wherein each of these moieties may be optionally substituted; R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7Rπ, C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR12, halo-substituted-Ci-4 alkyl, C1-4 alkyl, ZC(Z)Ri2, NRιoC(Z)Ri6, or (CRιoR2θ)vNRioR20 and which, for other positions of substitution, is halogen, cyano, C(Z)NRi3Ri4, C(Z)OR3, (CRioR20)m"COR3, S(O)mR3, OR3, halo-substituted-Ci-4 alkyl, C1-4 alkyl,
(CRi0R20)m"NRl0C(Z)R3, NRi0S(O)m'R8, NR╬╣0S(O)m'NR7R╬╣7, ZC(Z)R3 or (CRioR20)m"NRl3Rl4; Z is oxygen or sulfur; n is 0, or an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2;
R2 is hydrogen, C(H)(A)(R22), (CRl╬╕R23)n OR9, (CR╬╣oR23)nORl l, -ioalkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylCi-io alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-ioalkyl, heterocyclyl, heterocyclylCi- o alkyl, (CR╬╣oR23)nS(O)mRi8, (CR╬╣oR23)nNHS(O)2Rl8, (CR╬╣oR23)nNRl3Rl4,
(CRioR23)nNO2, (CR╬╣0R23)nCN, (CR╬╣0R23)nS(O)m'NRi3R╬╣4, (CRioR230)nC(Z)Rn, (CRioR23)nOC(Z)Rn, (CR╬╣oR23)nC(Z)ORn, (CR╬╣oR23)nC(Z)NR╬╣3Ri4, (CR╬╣0R23)nC(Z)NR╬╣ 1OR9,
(CR╬╣oR23)nNRl╬╕C(Z)R╬╣ ╬╣, (CR╬╣oR23)nN l╬╕C(Z)NR╬╣3Rl4. (CRioR23)nN(OR6)C(Z)NRi3Rl4, (CRi0R23)nN(OR6)C(Z)R╬╣ i,
(CR╬╣oR23)nC(=NOR6)Rl l, (CR╬╣oR23)nNRi╬╕C(=NRi9)NRi3Rl4, (CR╬╣oR23)nOC(Z)NRi3Rl4, (CRl╬╕R23)nNRl╬╕C(Z)NR╬╣3Rl4, (CR╬╣oR23)nNRioC(Z)OR╬╣o, 5-(Ri8)-l,2,4-oxadizaol-3-yl or 4-(Ri2)-5- (Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; and wherein the cycloalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl moieties may all be optionally substituted;
A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted
Ci-io alkyl; R22 is an optionally substituted CJ. IQ alkyl; R is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; and wherein each of these moieties may be optionally substituted; R3 is heterocyclyl, heterocyclylCi-io alkyl or Rs;
R5 is hydrogen, Ci-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl; R7 and R17 is each independently selected from hydrogen or Ci-4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; R8 is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CRioR20)nORl l, (CRioR20)nS(O)mRl8, (CRioR20)nNHS(O)2Rl8.
(CR╬╣oR2╬╕)nNRl3Rl4; and wherein the aryl, arylalkyl, heteroaryl, heteroarylalkyl may be optionally substituted; R9 is hydrogen, C(Z)R╬╣ 1 or optionally substituted Ci-io alkyl, S(O)2Rl8> optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl; R o and R20 are each independently selected from hydrogen or Ci-4 alkyl; Rl 1 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl
Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylC -io alkyl; and wherein these moieties may be optionally substituted; Rl2 is hydrogen or Ri6; R13 and R14 is each independently selected from hydrogen or optionally substituted
Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of
5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9; Ri5 is Rio or C(Z)-Ci-4 _lkyl;
Rl6 is Ci-4 alkyl, halo-substituted-Ci-4 alkyl, or C3-7 cycloalkyl;
Rl8 is Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-C -ioalkyl, heteroaryl or heteroaryl -ioalkyl; Rl9 is hydrogen, cyano, C -4 alkyl, C3-7 cycloalkyl or aryl; R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or a heterocyclylC -4 alkyl moiety, all of which moieties may be optionally substituted; or a pharmaceutically acceptable salt thereof.
15. The compound according to Claim 14 wherein the Rj optional substituent is Y.
16. The compound according to Claim 15 wherein the Ra moiety is alkyl, aryl, or arylalkyl.
17. The compound according to Claim 14 wherein R4 is an optionally substituted phenyl.
18. The compound according to Claim 17 wherein the phenyl is substituted one or more times independently by halogen, SR5, S(O)R5, OR12, halo-substituted-Ci-4 alkyl, or Ci .4 alkyl.
19. The compound according to Claim 14 wherein R2 is hydrogen,
C(H)(A)(R22), aryl, arylalkyl, heterocyclic, heterocyclicalkyl, heteroaryl and heterocyclic alkyl; and wherein the aryl, heteroaryl or heterocyclic containing moieties may be optionally substituted.
20. The compound according to Claim 19 wherein R2 is an optionally substituted aryl.
21. A pharmaceutical composition comprising an effective amount of a compound according to any of Claims 14 to 20 and a pharmaceutically acceptable carrier or diluent.
22. A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound of Formula (I) according to any of Claims 14 to 20.
23. The method according to Claim 22 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resoφtion disease, osteoporosis, restenosis, stroke, CNS injury, cardiac and renal reperfusion injury, chronic renal failure, congestive heart failure, angiogenic diseases, thrombosis, glomerularnephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermititis, psoriasis, sunburn, conjunctivitis, or rhinovirus infection.
24. A compound of the formula :
Figure imgf000061_0001
wherein
Rl is a 4-pyridyl, or pyrimidin-4-yl ring, which ring is optionally substituted one or more times with Y, C -4 alkyl, halogen, hydroxyl, Ci-4 alkoxy, Ci-4 alkylthio, Ci-4 alkylsulfinyl, CH2OR12, amino, mono and di- Ci-6 alkyl substituted amino, N(R╬╣o)C(O)Rb or an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from oxygen, sulfur or NR 15; Y is X╬╣-Ra;
X is sulfur, oxygen, or NH; Ra is Ci-6alkyl, aryl, arylCi-6alkyl, heterocyclic, heterocyclylCi-6 alkyl, heteroaryl, or heteroarylCi-6alkyl, wherein each of these moieties may be optionally substituted; R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, all of which may be optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-l-yl, 5-naphth-2-yl or 6-naphth-2- yl substituent, is halogen, cyano, nitro, C(Z)NR7Ri7, C(Z)ORi6, (CRioR20)vCORi2, SR5, SOR5, OR12, halo-substituted-Ci-4 alkyl, C1-4 alkyl, ZC(Z)Ri2, NR╬╣oC(Z)Ri6, or (CR╬╣oR2╬╕)vNRl╬╕R20 and which, for other positions of substitution, is halogen, cyano, C(Z)NR 3Ri4, C(Z)OR3, (CRioR20)m"COR3, S(O)mR3, OR3, halo-substituted-Ci-4 alkyl, C╬╝ alkyl,
(CRioR2╬╕)m"NRl╬╕C(Z)R3, NR╬╣0S(O)m >R8, NR╬╣0S(O)m'NR7Rl7, ZC(Z)R3 or (CRi0R20)m"NRi3Rl4;
Z is oxygen or sulfur; n is 0, or an integer having a value of 1 to 10; m is 0, or the integer 1 or 2; m' is an integer having a value of 1 or 2, m" is 0, or an integer having a value of 1 to 5; v is 0, or an integer having a value of 1 or 2; R2 is hydrogen, -C(H)(A)(R22), (CRl╬╕R23)n OR9, (CR╬╣oR23)nORn, Ci-ioalkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3_7cycloalkylCi-io alkyl, C5-7 cycloalkenyl, C5-7 cycloalkenyl Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylC -ioalkyl, heterocyclyl, heterocyclylCi-io alkyl, (CR╬╣oR23)nS(O)mR╬╣8, (CR╬╣oR23)nNHS(O) Rl8, (CR╬╣0R23)nNRl3Rl4,
(CRl╬╕R23)nNO2, (CRi0R23)nCN, (CR╬╣0R23)nS(O)m'NRi3Rl4, (CRioR230)nC(Z)Rn, (CR╬╣oR23)nOC(Z)Rn, (CR╬╣oR23)nC(Z)ORn, (CR╬╣oR23)nC(Z)NR╬╣3Rl4, (CR╬╣0R23)nC(Z)NR╬╣ 1OR9, (CR╬╣0R23)nNRl╬╕C(Z)R╬╣ 1, (CR╬╣oR23)nNRloC(Z)NR╬╣3R╬╣4, (CR╬╣oR23)nN(OR6)C(Z)NRi3Rl4, (CR╬╣0R23)nN(OR6)C(Z)R╬╣ i,
(CRioR23)nC(=NOR6)Rl 1, (CRi0R23)nNRl╬╕C(=NR╬╣9)NR╬╣3Rl4, (CRl╬╕R23)nOC(Z)NRi3Ri4, (CRi╬╕R23)nNRl╬╕C(Z)NR╬╣3Ri4, (CRioR23)nNRl╬╕C(Z)ORio, 5-(Ri8)-l,2,4-oxadizaol-3-yl or 4-(Ri2)-5- (Rl8Rl9)-4,5-dihydro-l,2,4-oxadiazol-3-yl; and wherein the cycloalkyl, cycloalkyl alkyl, aryl, arylalkyl, heteroaryl, heteroaryl alkyl, heterocyclic and heterocyclic alkyl moieties may be optionally substituted; A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted
C\.10 alkyl; R22 is an optionally substituted C .\Q alkyl; Rb is hydrogen, C -6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl; and wherein each of these moieties may be optionally substituted; R3 is heterocyclyl, heterocyclylCi-io alkyl or Rg;
R5 is hydrogen, Cj-4 alkyl, C2-4 alkenyl, C2-4 alkynyl or NR7R17, excluding the moieties SR5 being SNR7R17 and SOR5 being SOH;
R6 is hydrogen, a pharmaceutically acceptable cation, Ci-io alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4 alkyl, heterocyclic, aroyl, or Ci-io alkanoyl; R7 and R17 is each independently selected from hydrogen or Ci-4 alkyl or R7 and R17 together with the nitrogen to which they are attached form a heterocyclic ring of 5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR15; R8 is Ci-io alkyl, halo-substituted Ci-io alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, arylCi-io alkyl, heteroaryl, heteroarylCi-io alkyl, (CRioR20)nORl l, (CR╬╣oR2╬╕)nS(O)mR╬╣8) (CR╬╣0R20)nNHS(O)2Rl8, (CRioR20)nNRl3Rl4; and wherein the aryl, arylalkyl, heteroaryl, heteroaryl alkyl moieties may be optionally substituted; R9 is hydrogen, C(Z)Ri 1 or optionally substituted Ci-io alkyl, S(O)2Rl8> optionally substituted aryl or optionally substituted aryl-C -4 alkyl; Rio and R20 are each independently selected from hydrogen or Ci-4 alkyl; Rl 1 is hydrogen, Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl
Ci-ioalkyl, aryl, arylCi-io alkyl, heteroaryl or heteroarylCi-io alkyl, wherein all of these moieites may be optionally substituted; Rl2 is hydrogen or Ri6; R13 and R14 is each independently selected from hydrogen or optionally substituted
Ci-4 alkyl, optionally substituted aryl or optionally substituted aryl-Ci-4 alkyl, or together with the nitrogen which they are attached form a heterocyclic ring of
5 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR9 ; Ri5 is R╬╣o or C(Z)-Ci-4 alkyl;
Rl6 is Ci-4 alkyl, halo-substituted-Ci-4 alkyl, or C3-7 cycloalkyl;
Rl8 is Ci-io alkyl, C3-7 cycloalkyl, heterocyclyl, aryl, aryli-ioalkyl, heterocyclyl, heterocyclyl-Ci-ioalkyl, heteroaryl or heteroaryl i-ioalkyl; Rl9 is hydrogen, cyano, Ci-4 alkyl, C3-7 cycloalkyl or aryl; R23 is hydrogen, Ci-6 alkyl, C3-7 cycloalkyl, aryl, arylCi-4 alkyl, heteroaryl, heteroarylCi-4alkyl, heterocyclyl, or heterocyclylCi-4 alkyl moiety, all of which may be optionally substituted; or a pharmaceutically acceptable salt thereof.
25. The compound according to Claim 24 wherein the Ri optional substituent is Y.
26. The compound according to Claim 25 wherein the Ra moiety is alkyl, aryl, or arylalkyl.
27. The compound according to Claim 24 wherein R4 is an optionally substituted phenyl.
28. The compound according to Claim 27 wherein the phenyl is substituted one or more times independently by halogen, SR5, S(O)R5, OR12, halo-substituted-Ci-4 alkyl, or C 1.4 alkyl.
29. The compound according to Claim 24 wherein R2 is hydrogen, C(H)(A)(R22)┬╗ aryl, arylalkyl, heterocyclic, heterocyclicalkyl, heteroaryl and heterocyclic alkyl; and wherein the aryl, heteroaryl or heteoryclic containing moieties may be optionally substitued.
30. The compound according to Claim 29 wherein R2 is an optionally substituted aryl.
31. A pharmaceutical composition comprising an effective amount of a compound according to any of Claims 24 to 30 and a pharmaceutically acceptable carrier or diluent.
32. A method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound of Formula (I) according to any of Claims 24 to 32.
33. The method according to Claim 32 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcososis, bone resoφtion disease, osteoporosis, restenosis, stroke, CNS injury, cardiac and renal reperfusion injury, chronic renal failure, congestive heart failure, angiogenic diseases, thrombosis, glomerularnephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermititis, psoriasis, sunburn, conjunctivitis, or rhinovirus infection.
PCT/US1999/018640 1998-08-20 1999-08-17 Novel substituted triazole compounds WO2000010563A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP99942232A EP1112070B1 (en) 1998-08-20 1999-08-17 Novel substituted triazole compounds
DE69917296T DE69917296T2 (en) 1998-08-20 1999-08-17 NEW SUBSTITUTED TRIAZONE COMPOUNDS
AT99942232T ATE266399T1 (en) 1998-08-20 1999-08-17 NEW SUBSTITUTED TRIAZOLE COMPOUNDS
US09/762,809 US6599910B1 (en) 1998-08-20 1999-08-17 Substituted triazole compounds
CA002341370A CA2341370A1 (en) 1998-08-20 1999-08-17 Novel substituted triazole compounds
JP2000565884A JP2003525201A (en) 1998-08-20 1999-08-17 New substituted triazole compounds
US10/401,249 US7223760B2 (en) 1998-08-20 2003-03-26 Substituted triazole compounds

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9730298P 1998-08-20 1998-08-20
US9732298P 1998-08-20 1998-08-20
US9730098P 1998-08-20 1998-08-20
US60/097,302 1998-08-20
US60/097,300 1998-08-20
US60/097,322 1998-08-20

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09/762,809 A-371-Of-International US6599910B1 (en) 1998-08-20 1999-08-17 Substituted triazole compounds
US09762809 A-371-Of-International 1999-08-17
US10/401,249 Division US7223760B2 (en) 1998-08-20 2003-03-26 Substituted triazole compounds

Publications (1)

Publication Number Publication Date
WO2000010563A1 true WO2000010563A1 (en) 2000-03-02

Family

ID=27378362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/018640 WO2000010563A1 (en) 1998-08-20 1999-08-17 Novel substituted triazole compounds

Country Status (8)

Country Link
US (2) US6599910B1 (en)
EP (1) EP1112070B1 (en)
JP (1) JP2003525201A (en)
AT (1) ATE266399T1 (en)
CA (1) CA2341370A1 (en)
DE (1) DE69917296T2 (en)
ES (1) ES2221426T3 (en)
WO (1) WO2000010563A1 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539550B1 (en) * 1991-05-25 1996-03-20 ITT Automotive Europe GmbH Windscreen cleaning installation, especially for motor vehicles
WO2001009106A1 (en) * 1999-08-02 2001-02-08 Smithkline Beecham P.L.C. Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
WO2002040476A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Pyridyl-substituted triazoles as tgf inhibitors
WO2002072576A1 (en) * 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
WO2002088113A1 (en) * 2001-04-30 2002-11-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
WO2002094814A1 (en) * 2001-05-08 2002-11-28 Schering Aktiengesellschaft 3,5-diamino-1,2,4-triazoles as kinase inhibitors
WO2003040110A1 (en) 2001-11-09 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Triazole derivatives as cyclooxygenase (cox) inhibitors
WO2003042211A1 (en) * 2001-11-15 2003-05-22 Smithkline Beecham Corporation Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
WO2003035626A3 (en) * 2001-10-23 2003-11-06 Applied Research Systems Azole derivatives and pharmaceutical compositions containing them
WO2004014900A1 (en) * 2002-08-09 2004-02-19 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
WO2004046120A2 (en) * 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
US6790846B2 (en) 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
WO2005013982A1 (en) * 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
EP1676574A2 (en) 2004-12-30 2006-07-05 Johnson &amp; Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
WO2006117657A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
WO2007049820A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
WO2008142031A1 (en) 2007-05-18 2008-11-27 Institut Curie P38alpha as a therapeutic target in bladder carcinoma
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2012146362A1 (en) * 2011-04-26 2012-11-01 King Saud University Triazole compounds as potential anti-inflammatory agents
WO2013049591A2 (en) * 2011-09-29 2013-04-04 Verseon Corporation Dual inhibitor compounds and methods of use thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases
US11452713B2 (en) 2016-02-29 2022-09-27 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods for treating low-proliferative disseminated tumor cells

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759410B1 (en) * 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
AR039241A1 (en) * 2002-04-04 2005-02-16 Biogen Inc HETEROARILOS TRISUSTITUIDOS AND METHODS FOR ITS PRODUCTION AND USE OF THE SAME
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
EP1802585A1 (en) * 2004-09-03 2007-07-04 Memory Pharmaceuticals Corporation 4-substituted 4,6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
CA2747398C (en) 2008-12-17 2023-06-20 The Scripps Research Institute Generation and maintenance of stem cells
EP2763533B1 (en) 2011-10-06 2021-12-29 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
WO2013162027A1 (en) 2012-04-27 2013-10-31 学校法人 慶應義塾 Neuronal differentiation promoter
TW201422610A (en) 2012-11-15 2014-06-16 Merck Sharp & Dohme Secondary alcohol substituted triazoles as PDE10 inhibitors
WO2014078217A1 (en) * 2012-11-15 2014-05-22 Merck Sharp & Dohme Corp. Cyclopropyl imidazopyridine pde10 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162217A1 (en) * 1984-03-16 1985-11-27 Ciba-Geigy Ag 1,2,4-Triazacycloalcadiene derivatives

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE162217C (en) *
US2833779A (en) * 1956-10-29 1958-05-06 American Cyanamid Co Substituted pyrazoles
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (en) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
JPS60226882A (en) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd Novel pyrimidopyrimidine derivative
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
CA2084290A1 (en) 1990-06-12 1991-12-13 Jerry L. Adams Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
FR2665898B1 (en) * 1990-08-20 1994-03-11 Sanofi DERIVATIVES OF AMIDO-3 PYRAZOLE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
IE913473A1 (en) * 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
WO1992010190A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
WO1992010498A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
JP3375659B2 (en) * 1991-03-28 2003-02-10 テキサス インスツルメンツ インコーポレイテツド Method of forming electrostatic discharge protection circuit
US5302387A (en) 1991-11-06 1994-04-12 Mycogen Corporation Bacillus thuringiensis isolates active against cockroaches and genes encoding cockroach-active toxins
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
JP3264492B2 (en) 1992-01-13 2002-03-11 スミスクライン・ビーチャム・コーポレイション Pyridyl-substituted imidazole
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US5716972A (en) * 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US6008235A (en) 1992-01-13 1999-12-28 Smithkline Beecham Corporation Pyridyl substituted imidazoles
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9303993D0 (en) * 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
US5690959A (en) 1993-05-29 1997-11-25 Smithkline Beecham Corporation Pharmaceutical thermal infusion process
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds
ES2140561T3 (en) * 1993-09-17 2000-03-01 Smithkline Beecham Corp DRUG UNION PROTEIN.
US5869043A (en) * 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
JP3588116B2 (en) * 1993-10-01 2004-11-10 ノバルティス アクチェンゲゼルシャフト Pharmacologically active pyrimidineamine derivatives and process for their production
AU693475B2 (en) * 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
JPH09505055A (en) * 1993-11-08 1997-05-20 スミスクライン・ビーチャム・コーポレイション Oxazole for treatment of cytokine-mediated diseases
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
JPH10510540A (en) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド Irrigation solutions and methods for controlling pain, inflammation and convulsions
EP0799051B1 (en) * 1994-12-12 2005-07-27 Omeros Corporation Irrigation solution and use thereof for perioperatively inhibiting pain, inflammation and spasm at a wound
CA2210322A1 (en) 1995-01-12 1996-07-18 Smithkline Beecham Corporation Novel compounds
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
EP0900083B1 (en) 1996-01-11 2003-08-20 Smithkline Beecham Corporation Novel substituted imidazole compounds
JP2001508395A (en) 1996-01-11 2001-06-26 スミスクライン・ビーチャム・コーポレイション New cycloalkyl-substituted imidazole
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2000507224A (en) 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Use of CSAID compounds as inhibitors of angiogenesis
WO1997033883A1 (en) 1996-03-13 1997-09-18 Smithkline Beecham Corporation Novel pyrimidine compounds useful in treating cytokine mediated diseases
JP2000507545A (en) 1996-03-25 2000-06-20 スミスクライン・ビーチャム・コーポレイション Novel treatment for CNS injury
WO1997035856A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
US5948786A (en) * 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
US6875769B2 (en) * 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
EP0922042A1 (en) 1996-08-09 1999-06-16 Smithkline Beecham Corporation Novel piperazine containing compounds
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AU5147598A (en) 1996-10-17 1998-05-11 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
DK0948495T3 (en) * 1996-11-19 2004-06-01 Amgen Inc Aryl- and heteroaryl-substituted condensed pyrrole as anti-inflammatory agents
US5724708A (en) * 1996-12-03 1998-03-10 Textron, Inc. End connector assembly for watchband
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
ES2270520T3 (en) * 1997-06-12 2007-04-01 Aventis Pharma Limited IMIDAZOLIL-CYCLICAL ACETALS.
US6562832B1 (en) * 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (en) 1997-07-02 2001-07-04 Smithkline Beecham Corp IMIDAZOL SUBSTITUTE COMPOSITE, PHARMACEUTICAL COMPOSITION CONTAINING IT, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCEDURE FOR SUPREPARATION
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
JP2002509537A (en) 1997-07-02 2002-03-26 スミスクライン・ビーチャム・コーポレイション New cycloalkyl-substituted imidazole compounds
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001518507A (en) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション New cycloalkenyl substituted compounds
WO1999018942A1 (en) 1997-10-10 1999-04-22 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
JP2002515891A (en) 1997-12-19 2002-05-28 スミスクライン・ビーチャム・コーポレイション New piperidine-containing compounds
WO1999032121A1 (en) 1997-12-19 1999-07-01 Smithkline Beecham Corporation Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
US6148226A (en) 1998-02-13 2000-11-14 Aerospace Research Technologies Inc. Optical imaging through scattering media: fit to an inhomogeneous diffusion model for differentiation
ID27285A (en) 1998-05-15 2001-03-22 Astrazeneca Ab BENZAMIDA DEPOSIT FOR TREATMENT DISEASE EXPANDED BY SITOKINA
DE69921986T2 (en) * 1998-05-15 2005-12-22 Astrazeneca Ab BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKIN-MEDIATED DISEASES
US6130235A (en) 1998-05-22 2000-10-10 Scios Inc. Compounds and methods to treat cardiac failure and other disorders
WO1999061437A1 (en) 1998-05-22 1999-12-02 Smithkline Beecham Corporation Novel 2-alkyl substituted imidazole compounds
CA2333157A1 (en) 1998-05-26 1999-12-02 Smithkline Beecham Corporation Novel substituted imidazole compounds
AU4429799A (en) 1998-06-12 1999-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AU4395399A (en) 1998-07-02 2000-01-24 Sankyo Company Limited Five-membered heteroaryl compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
MXPA01000895A (en) * 1998-08-04 2002-08-20 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines.
CA2341370A1 (en) 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
KR20010082184A (en) * 1998-08-28 2001-08-29 추후제출 Inhibitors of p38-α Kinase
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
AU762245B2 (en) * 1998-09-18 2003-06-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
SK285520B6 (en) * 1998-09-25 2007-03-01 Astrazeneca Ab Amide derivatives, process for their preparation, pharmaceutical composition containing them and their use in manufacture of medicament in treatment of medical conditions mediated by cytokines
EP1117653B1 (en) * 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
JP2002526388A (en) 1998-10-07 2002-08-20 スミスクライン・ビーチャム・コーポレイション Novel measures to manage seizures
PL347432A1 (en) 1998-10-23 2002-04-08 Hoffmann La Roche Bicyclic nitrogen heterocycles
DE69914357T2 (en) 1998-11-04 2004-11-11 Smithkline Beecham Corp. PYRIDIN-4-YL OR PYRIMIDIN-4-YL SUBSTITUTED PYRAZINE
JP2002530404A (en) 1998-11-20 2002-09-17 ジー・ディー・サール・アンド・カンパニー Method for producing 5-substituted pyrazoles using dithiethane
AU765492B2 (en) * 1998-12-25 2003-09-18 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
EP1140083A4 (en) 1999-01-08 2004-01-02 Smithkline Beecham Corp Novel compounds
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6358959B1 (en) * 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6509361B1 (en) * 1999-05-12 2003-01-21 Pharmacia Corporation 1,5-Diaryl substituted pyrazoles as p38 kinase inhibitors
US6541477B2 (en) * 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
US20020002169A1 (en) * 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US6525046B1 (en) * 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (en) * 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー New compounds
US20040092532A1 (en) * 2001-10-19 2004-05-13 Griswold Don E Use of p38 inhibitors for the treatment of smoke inhalation
US20040097473A1 (en) * 2001-10-19 2004-05-20 Griswold Don E Use of p38 inhibitors for the treatment of smoke inhalation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162217A1 (en) * 1984-03-16 1985-11-27 Ciba-Geigy Ag 1,2,4-Triazacycloalcadiene derivatives

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539550B1 (en) * 1991-05-25 1996-03-20 ITT Automotive Europe GmbH Windscreen cleaning installation, especially for motor vehicles
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6599910B1 (en) 1998-08-20 2003-07-29 Smithkline Beecham Corporation Substituted triazole compounds
WO2001009106A1 (en) * 1999-08-02 2001-02-08 Smithkline Beecham P.L.C. Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
WO2002040476A1 (en) * 2000-11-16 2002-05-23 Smithkline Beecham Corporation Pyridyl-substituted triazoles as tgf inhibitors
WO2002072576A1 (en) * 2001-03-09 2002-09-19 Pfizer Products Inc. Benzimidazole anti-inflammatory compounds
WO2002088113A1 (en) * 2001-04-30 2002-11-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6727364B2 (en) 2001-04-30 2004-04-27 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
WO2002094814A1 (en) * 2001-05-08 2002-11-28 Schering Aktiengesellschaft 3,5-diamino-1,2,4-triazoles as kinase inhibitors
US6790846B2 (en) 2001-05-24 2004-09-14 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
US6919346B2 (en) 2001-05-24 2005-07-19 The Procter & Gamble Company Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity
AU2002359291C1 (en) * 2001-10-23 2008-11-20 Merck Serono Sa Azole derivatives and pharmaceutical compositions containing them
US7541375B2 (en) 2001-10-23 2009-06-02 Laboratoires Serono Sa Azole derivatives and pharmaceutical compositions containing them
WO2003035626A3 (en) * 2001-10-23 2003-11-06 Applied Research Systems Azole derivatives and pharmaceutical compositions containing them
AU2002359291B8 (en) * 2001-10-23 2008-04-17 Merck Serono Sa Azole derivatives and pharmaceutical compositions containing them
AU2002359291B2 (en) * 2001-10-23 2008-04-03 Merck Serono Sa Azole derivatives and pharmaceutical compositions containing them
US7253199B2 (en) 2001-10-23 2007-08-07 Applied Research Systems Ars Holding N.V. Azole derivatives and pharmaceutical compositions containing them
CN100338042C (en) * 2001-11-09 2007-09-19 安斯泰来制药有限公司 Triazole derivatives as cyclooxygenase (COX) inhibitors
US6927230B2 (en) 2001-11-09 2005-08-09 Fujisawa Pharmaceutical Co., Ltd. Triazole derivatives
WO2003040110A1 (en) 2001-11-09 2003-05-15 Fujisawa Pharmaceutical Co., Ltd. Triazole derivatives as cyclooxygenase (cox) inhibitors
JP2007169290A (en) * 2001-11-09 2007-07-05 Astellas Pharma Inc Triazole derivative
WO2003042211A1 (en) * 2001-11-15 2003-05-22 Smithkline Beecham Corporation Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
EP1707205A2 (en) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
WO2004014900A1 (en) * 2002-08-09 2004-02-19 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
US7320995B2 (en) 2002-08-09 2008-01-22 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
US7268139B2 (en) 2002-08-29 2007-09-11 Scios, Inc. Methods of promoting osteogenesis
WO2004046120A3 (en) * 2002-11-15 2004-08-12 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
WO2004046120A2 (en) * 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
US7902239B2 (en) 2002-11-15 2011-03-08 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
US7279469B2 (en) 2002-11-15 2007-10-09 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases
JP2007501257A (en) * 2003-08-06 2007-01-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド Aminotriazole compounds useful as inhibitors of protein kinases
US7226920B2 (en) 2003-08-06 2007-06-05 Vertex Pharmaceuticals Inc. Aminotriazole compounds useful as inhibitors of protein kinases
AU2004263148B2 (en) * 2003-08-06 2008-08-21 Vertex Pharmaceuticals, Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
US7598245B2 (en) 2003-08-06 2009-10-06 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
WO2005013982A1 (en) * 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
JP4889489B2 (en) * 2003-08-06 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Aminotriazole compounds useful as inhibitors of protein kinases
US7244441B2 (en) 2003-09-25 2007-07-17 Scios, Inc. Stents and intra-luminal prostheses containing map kinase inhibitors
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
EP2878297A1 (en) 2004-12-24 2015-06-03 Boehringer Ingelheim International GmbH Medicaments for the treatment or prevention of fibrotic diseases
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
EP1676574A2 (en) 2004-12-30 2006-07-05 Johnson &amp; Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
WO2006117657A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
WO2007049820A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
WO2008142031A1 (en) 2007-05-18 2008-11-27 Institut Curie P38alpha as a therapeutic target in bladder carcinoma
EP2527335A1 (en) * 2011-04-26 2012-11-28 King Saud University Triazole compounds as anti-inflammatory agents
US8829016B2 (en) 2011-04-26 2014-09-09 King Saud University Triazole compounds as potential anti-inflammatory agents
WO2012146362A1 (en) * 2011-04-26 2012-11-01 King Saud University Triazole compounds as potential anti-inflammatory agents
WO2013049591A2 (en) * 2011-09-29 2013-04-04 Verseon Corporation Dual inhibitor compounds and methods of use thereof
WO2013049591A3 (en) * 2011-09-29 2013-05-23 Verseon Corporation Dual inhibitor compounds and methods of use thereof
US11452713B2 (en) 2016-02-29 2022-09-27 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods for treating low-proliferative disseminated tumor cells
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Also Published As

Publication number Publication date
EP1112070A1 (en) 2001-07-04
US20030229110A1 (en) 2003-12-11
US7223760B2 (en) 2007-05-29
DE69917296T2 (en) 2005-05-25
ATE266399T1 (en) 2004-05-15
ES2221426T3 (en) 2004-12-16
CA2341370A1 (en) 2000-03-02
JP2003525201A (en) 2003-08-26
EP1112070A4 (en) 2002-01-02
DE69917296D1 (en) 2004-06-17
US6599910B1 (en) 2003-07-29
EP1112070B1 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
US6599910B1 (en) Substituted triazole compounds
AU760527C (en) Novel 2-alkyl substituted imidazole compounds
US6335340B1 (en) compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US6774127B2 (en) Pyrazole and pyrazoline substituted compounds
US6362193B1 (en) Cycloalkenyl substituted compounds
WO1999001136A1 (en) Novel substituted imidazole compounds
US6610695B1 (en) Aryloxy substituted pyrimidine imidazole compounds
WO1999001130A1 (en) Novel substituted imidazole compounds
US6548503B1 (en) Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US6469018B1 (en) Compounds
AU737637C (en) Novel substituted imidazole compounds
NZ520906A (en) 2(alkyl)-, 5(4-pyrimidinyl)- substituted imidazole derivatives and pharmaceuticals thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2341370

Country of ref document: CA

Ref country code: CA

Ref document number: 2341370

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999942232

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09762809

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999942232

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1999942232

Country of ref document: EP